Clinigen 
Welcome,         Profile    Billing    Logout  
 3 Products   510 Diseases  3 Products   114 Trials   1415 News 
125 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Actimmune (interferon gamma-1 b) / Clinigen, Amgen
2012-002491-14: The effects of the drug interferon-gamma on suppression of the immune system in patients with sepsis De effecten van het geneesmiddel interferon-gamma op onderdrukking van het immuunsysteem veroorzaakt door sepsis.

Ongoing
3
20
Europe
Recombinant human interferon-gamma, L03A B03, Immukine, Immukine
Radboud University Nijmegen Medical Centre, Radboud University Nijmegen Medical Centre
Sepsis-induced immunoparalysis (SIRS, Sepsis, Septic shock) Sepsis geïnduceerde immuunparalyse
 
 
2015-002432-40: Safety and Efficacy of yIFN treatment in Friedreich ataxia Sicurezza ed efficacia del trattamento con Interferone gamma (¿IFN) nell'Atassia di Friedreich

Not yet recruiting
2
12
Europe
Imukin, Solution for injection, IMUKIN - 6 FLACONI 0.5 ML 100 MCG
ASSOCIAZIONE "LA NOSTRA FAMIGLIA" - SEZIONE SCIENTIFICA I.R.C.C.S. "E.MEDEA", Associazione di pazienti
FRDA is a progressive neurodegenerative disease inherited as recessive trait. It manifests itself usually in adolescence and affects various systems including the central and peripheral nervous system (balance, coordination, speech and sensitivity), the heart with hypertrophic cardiomyopathy, the bones with skeletal deformities (scoliosis, claw foot) and in some cases diabetes mellitus. The disease causes severe and progressive disability, significantly reducing the life expectancy of patients. FRDA ¿ una malattia neurodegenerativa a carattere progressivo trasmessa in forma autosomica recessiva. Esordisce in particolare in et¿ adolescenziale e colpisce vari sistemi tra cui il nervoso centrale e periferico (disturbi dell¿equilibrio, coordinazione, disturbi del linguaggio e della sensibilit¿), il cuore con cardiomiopatia ipertrofica, le ossa con deformit¿ scheletriche (scoliosi, piede cavo) ed in alcuni casi diabete mellito. La malattia causa disabilit¿ severa e progressiva, riduce in mo, FRDA is a progressive neurodegenerative disease inherited as recessive trait. The disease manifests itself usually in adolescence FRDA ¿ una malattia neurodegenerativa a carattere progressivo che viene trasmessa in forma autosomica recessiva. La malattia esordisce in particolare in et¿ adolescenziale., Diseases [C] - Nervous System Diseases [C10]
 
 
NCT03063632: Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma

Completed
2
28
US
Interferon Gamma-1b, Actimmune, gamma Interferon 1B, IFN-g-1b, IFN-gamma 1b, IFNg-1b, Interferon gamma-1b, Recombinant, N(Sup 2)-L-Methionyl-1-139-Interferon G, N(sup 2)-L-Methionyl-1-139-interferon gamma (Human Lymphocyte Protein Moiety Reduced), Recombinant Interferon Gamma-1b, Laboratory Biomarker Analysis, Pembrolizumab, BCD-201, Keytruda, Lambrolizumab, MK-3475, Pembrolizumab Biosimilar BCD-201, SCH 900475
National Cancer Institute (NCI)
Metastatic Myxoid Liposarcoma, Metastatic Round Cell Liposarcoma, Metastatic Synovial Sarcoma, Recurrent Mycosis Fungoides and Sezary Syndrome, Refractory Mycosis Fungoides and Sezary Syndrome, Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage II Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IVA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v7, Unresectable Synovial Sarcoma
04/21
03/23
PREV-HAP, NCT04793568 / 2020-000620-18: Human Recombinant Interferon Gamma-1b for the Prevention of Hospital-acquired Pneumonia in Critically Ill Patients: a Double-blind, International, Phase 2, Randomized, Placebo-controlled Trial - the Study

Active, not recruiting
2
109
Europe
Recombinant Interferon gamma 1b (IMUKIN®), Recombinant Interferon gamma 1b placebo
Nantes University Hospital
Critically Ill Patients
11/21
06/23
2020-003204-13: Safety and Efficacy of Immunotherapy in Patients With Candidemia Veiligheid en effectiviteit van Immuuntherapie bij patiënten met een uitgebreide schimmelinfectie

Ongoing
2
200
Europe
Immukin, Solution for injection, Immukin
Radboudumc, Hellenic Institute for the Study of Sepsis, Radboudumc, Hellenic Institute for the Study of Sepsis
Candidemia Candidemie, Systemic fungal infection Systemische schimmelinfectie, Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
ImmunoSep, NCT04990232 / 2020-005768-74: Personalized Immunotherapy in Sepsis

Completed
2
280
Europe
Anakinra or rhIFNγ, Imukin, Kineret, Placebo
Hellenic Institute for the Study of Sepsis
Sepsis
02/24
04/24
NCT06529731: Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation

Recruiting
2
45
US
Interferon gamma-1b, ACTIMMUNE®, Donor Leukocyte Infusion (DLI)
Sawa Ito, MD, Evans MDS Discovery Research Grant, Amgen, FDA Office of Orphan Products Development
Acute Myeloid Leukemia, Myelodysplastic Syndromes
10/27
10/27
NCT04979052: Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia

Recruiting
2
200
Europe, US
Interferon Gamma-1B, Immukin
Radboud University Medical Center, Horizon 2020 - European Commission
Candidemia
06/26
06/26
MCC-18936, NCT03112590: Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer

Completed
1/2
51
US
Interferon-gamma (IFN-γ), Actimmune®, signaling proteins, Paclitaxel, Abraxane®, Trastuzumab, Herceptin®, Pertuzumab, PERJETA®, monoclonal antibody, Post Therapy Surgery
H. Lee Moffitt Cancer Center and Research Institute, Horizon Pharma Ireland, Ltd., Dublin Ireland
Breast Cancer, Breast Cancer, Male, Breast Cancer Female, HER2-positive Breast Cancer
03/21
02/23
ATTAC-MCC, NCT03747484: Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer

Terminated
1/2
7
US
Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR, Autologous CD8+ and CD4+ T-cells transduced with TCR A2-MCC1, FH-MCVA2TCR, FH-MCVA2TCR Autologous CD8+ and CD4+ T-cells Transduced with TCR A2-MCC1, Avelumab, 1537032-82-8, Bavencio, Immunoglobulin G1-lambda1, Anti-(Homo sapiens CD274 (Programmed Death Ligand 1, PDL1, pd-l1, B7 Homolog 1, B7H1)), Homo sapiens Monoclonal Antibody, MSB-0010718C, MSB0010718C, Pembrolizumab, Anti-(Human Programmed Cell Death 1), Keytruda, Lambrolizumab, MK-3475, SCH 900475, Interferon Gamma-1b, 98059-61-1, Actimmune, gamma Interferon 1B, IFN-g-1b, IFN-gamma 1b, Recombinant Interferon Gamma-1b
Fred Hutchinson Cancer Center, National Cancer Institute (NCI), Affini-T Therapeutics, Inc.
Other Skin
01/24
01/24
NCT04628338: IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation

Completed
1
8
US
IFN-γ (interferon gamma-1b) injection, ACTIMMUNE®
Sawa Ito, MD, Horizon Pharma USA, Inc.
Myelodysplastic Syndromes, Myeloid Leukemia, Allogeneic Stem Cell Transplantation
10/23
10/23
Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
2007-006730-33: Estudio de los mecanismos implicados en la recuperación de linfocitos CD4+ propiciada por el tratamiento con Interleuquina 2 en pacientes bajo TARGA efectivo, pero con escasa ganancia de linfocitos CD4+. Papel del cotratamiento con antiinflamatorios no esteroideos.

Ongoing
4
40
Europe
PROLEUKIN 18 millones UI polvo para solución inyectable SC, IBUPROFENO ALTER 600 mg, PROLEUKIN 18 millones UI polvo para solución inyectable SC, IBUPROFENO ALTER 600 mg
Hospital Universitario Virgen del Rocío
Infección crónica por VIH
 
 
NCT00026312: Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma

Active, not recruiting
3
1449
Canada, US, RoW
Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2, Dinutuximab, Ch 14.18UTC, Ch14.18, Dinutuximab Beta, MOAB Ch14.18, monoclonal antibody Ch14.18, Qarziba, Unituxin, Isotretinoin, 13-cis retinoic acid, 13-cis-Retinoate, 13-cis-Retinoic Acid, 13-cis-Vitamin A Acid, 13-cRA, Absorica, Accure, Accutane, Amnesteem, cis-Retinoic Acid, Cistane, Claravis, Isotretinoinum, Isotrex, Isotrexin, Myorisan, Neovitamin A, Neovitamin A Acid, Oratane, Retinoicacid-13-cis, Ro 4-3780, Ro-4-3780, Roaccutan, Roaccutane, Roacutan, Sotret, ZENATANE, Laboratory Biomarker Analysis, Pharmacological Study, Quality-of-Life Assessment, Quality of Life Assessment, Sargramostim, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin
National Cancer Institute (NCI)
Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
01/12
03/26
2006-003746-42: Immunotherapy vs immuno-chemotherapy in patients with metastatic kidney carcinoma

Ongoing
3
210
Europe
PROLEUKIN*EV 1FL 18MUI 5ML, GEMZAR*INFUS 1FL 1G POLV, NAVELBINE 50*IV 50MG 5ML, PROLEUKIN*EV 1FL 18MUI 5ML, GEMZAR*INFUS 1FL 1G POLV, NAVELBINE 50*IV 50MG 5ML
OSPEDALE ONCOLOGICO DI BARI
metastatic kidney carcinoma
 
 
2010-020397-42: The efficacy of an antigenic marker lesion for the therapeutic effect in patients with multiple, Ta/T1, G1/G2, non-muscle invasive bladder cancer (NMIBC) treated with TUR followed by IL-2 instillation

Ongoing
3
66
Europe
NA, NA, Proleukin, Proleukin
VUmc Dept Urology
Multiple, Ta / T1, G1 / G2, non-muscle invasive bladder carcinoma
 
 
SIOPEN, NCT01704716: High Risk Neuroblastoma Study 1.8 of SIOP-Europe

Recruiting
3
3300
Europe, RoW
Vincristine, Aldesleukin, Interleukin 2, IL-2, IL2, ch14.18/CHO, anti GD2 antibody, Dinutuximab beta EUSA, Qarziba®, Carboplatin, Paraplatin, Etoposide, VP16, Cisplatin, CDDP, Cyclophosphamide, Endoxan, Doxorubicin, Adriamycin, G-CSF, Filgrastim, Busulfan, Busilvex, Myleran, Busulphan, Melphalan, Alkeran
St. Anna Kinderkrebsforschung
Neuroblastoma
09/21
09/26
NCT02278887 / 2013-005406-54: Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma

Completed
3
168
Europe
Translational research, tumor tissue, blood, Cyclophosphamide, chemotherapy, Fludarabine, Interleukin-2, Proleukin, Ipilimumab infusion, standard treatment
The Netherlands Cancer Institute, Copenhagen University Hospital at Herlev
Metastatic Melanoma
09/22
12/23
NCT03928275: The Response to Intralesional IL-2 and/or BCG Treatment for Cutaneous Metastatic Melanoma

Withdrawn
2/3
100
NA
Interleukin-2, Proleukin (Aldesleukin), Combination therapy Interleukin-2 and Bacillus Calmette Guerin, BCG, strain TICE (OncoTICE) and Proleukin (Aldesleukin)
Carman Giacomantonio, Nova Scotia Health Authority
Cutaneous Metastatic Melanoma
09/22
09/22
Tregs in ALS, NCT04055623: T-regulatory Cells in ALS

Active, not recruiting
2a
12
US
Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections, Individualized therapy Treg cell infusions + Interleukin-2 (IL-2), Proleukin is brand name for IL-2, Monthly placebo infusions + 3 times per week placebo injections, inactive drug, Proleukin is the brand name for IL-2
The Methodist Hospital Research Institute, Massachusetts General Hospital, The Center for Clinical and Translational Sciences (CCTS) Clinical Research Unit at The University of Texas Health Science Center at Houston, North East Amyotrophic Lateral Sclerosis Consortium
ALS (Amyotrophic Lateral Sclerosis)
05/22
08/22
NCT00101101: Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma

Completed
2
43
US
Cyclophosphamide, Cytoxan, Doxorubicin, adriamycin, Rubex, Vincristine, Oncovin, leurocristine, VCR, Prednisone, Deltasone, Liquid Pred, Meticorten, Orasone, Dexamethasone, Decadron, Dexasone, Diodex, Hexadrol, Autologous Tumor Cell-Based Vaccine, IL-2, interleukin-2, cytokine, aldesleukin
H. Lee Moffitt Cancer Center and Research Institute, National Cancer Institute (NCI), Lymphoma Research Foundation, Novartis
Lymphoma
10/12
06/21
2007-002139-94: Multiple dose Phase II study of IPH1101 in monotherapy or associated with a low dose of IL2 (2MIU) in non previously treated hepatitis C patients

Ongoing
2
28
Europe
Phosphostim 200, Proleukin 18 MUI, IPH1101, Proleukin 18MUI, Proleukin 18MUI
Innate Pharma
Non previously treated Hepatitis C patients
 
 
2006-006212-30: A Randomised, Open labelled, Phase II, Immunogenicity, and Exploratory Efficacy Evaluation of Therapeutic Immunisations +/- IL-2, GM-CSF and Growth Hormone in HIV-1 Infected Subjects Receiving Highly Active Anti-retroviral Therapy (HAART).

Ongoing
2
30
Europe
Saizen, IR103, Proleukin, Leukine, IR103 is a combination of Remune and Amplivax, Saizen, Proleukin, Leukine, Saizen, Proleukin, Leukine
Imperial College London
HIV-1
 
 
2007-007265-20: A Phase II open label randomized parallel group non comparative trial to assess efficacy and safety of the association of IPH1101 and IL-2 alone and in combination with dacarbazine, in patients with metastatic melanoma

Ongoing
2
6
Europe
Phosphostim 200, PROLEUKIN 18 MUI, Dacarbazine Mayne 600 mg, IPH1101, DTIC, PROLEUKIN 18 MUI, Dacarbazine Mayne 600 mg, poudre pour solution injectable, PROLEUKIN 18 MUI, Dacarbazine Mayne 600 mg, poudre pour solution injectable
Innate Pharma
metastatic melanoma
 
 
2009-012583-13: Phase II study of interleukin-2 and zoledronic acid as maintenance therapy in patients with multiple myeloma having undergone autograft

Ongoing
2
43
Europe
ZOMETA, PROLEUKIN, ZOMETA, PROLEUKIN
AZIENDA OSPEDALIERA PISANA
Patients with multiple myeloma having undergone autograft
 
 
2011-001474-25: Subcutaneous administration of Interleukin-2 prior to surgical intervention in case of sonographically and cytologically involved sentinel node

Ongoing
2
20
Europe
Proleukin, Proleukin
Klinik für Dermatologie, Venerologie und Allergologie; Charité - Universitätsmedizin Berlin, AG Voit (Research fund, administered by Prof. Christiane Voit)
The trial is planned in a neo-adjuvant setting for a 4-weeks period in Melanoma patients with stage III. The stage is to be discovered by ultrasound and veriefied by fine needle punctere and cytology.
 
 
2013-001188-22: Immunologic system stimulation as maintaining therapy in hematological cancer Stimolazione del sistema immunologico come terapia di mantenimento nel tumore ematologico

Ongoing
2
43
Europe
ZOMETA, PROLEUKIN, ZOMETA, PROLEUKIN
AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA, Regione Toscana e Ministero della Salute
Multiple Myeloma patients underwent to autologous bone marrow transplant Pazienti adulti affetti da mieloma multiplo sottoposto a trapianto di cellule staminali autologhe
 
 
2016-000581-31: RESTORE IMMUNE COMPETENCE AGAINST CANCER CELLS IN BREAST CARCINOMA RESISTANT TO STANDARD TREATMENTS ATTIVAZIONE DELLA RISPOSTA IMMUNITARIA IN PAZIENTI RESISTENTI AL TRATTAMENTO STANDARD - studio “TRANSLATE - breast”

Ongoing
2
28
Europe
ENDOXAN, PROLEUKIN, Coated tablet, Powder for solution for injection, ENDOXAN BAXTER - 50 MG COMPRESSE RIVESTITE 50 COMPRESSE, PROLEUKIN - INIETTABILE 1 FLAC 18.000.000 UI 1 ML
AZIENDA SANITARIA OSPEDALIERA S.CROCE E CARLE CUNEO, RETE ONCOLOGICA DEL PIEMONTE E VALLE D'AOSTA
METASTATIC BREAST CANCER (MBC) CARCINOMA MAMMARIO METASTATICO, METASTATIC BREAST CANCER (MBC) CARCINOMA MAMMARIO METASTATICO, Diseases [C] - Cancer [C04]
 
 
2016-000578-39: RESTORE IMMUNE COMPETENCE AGAINST CANCER CELLS IN METASTATIC COLON-RECTAL CARCINOMA RESISTANT TO STANDARD TREATMENTS TRANSLATE – Colon-rectal STUDY ATTIVAZIONE DELLA RISPOSTA IMMUNITARIA IN PAZIENTI RESISTENTI AL TRATTAMENTO STANDARD - studio “TRANSLATE – colon-retto”

Ongoing
2
28
Europe
ENDOXAN, proleukin, Coated tablet, Powder for solution for injection, ENDOXAN BAXTER - 50 MG COMPRESSE RIVESTITE 50 COMPRESSE, PROLEUKIN - INIETTABILE 1 FLAC 18.000.000 UI 1 ML
AZIENDA SANITARIA OSPEDALIERA S.CROCE E CARLE CUNEO, Rete Oncologica del Piemonte e valle d'Aosta
COLORECTAL METASTATIC CANCER CARCINOMA COLON-RETTO METASTATICO, COLORECTAL METASTATIC CANCER CARCINOMA COLON-RETTO METASTATICO, Diseases [C] - Cancer [C04]
 
 
2016-000580-17: RESTORE IMMUNE COMPETENCE AGAINST CANCER CELLS IN RENAL CELL CARCINOMA RESISTANT TO STANDARD TREATMENTS TRANSLATE – kidney STUDY ATTIVAZIONE DELLA RISPOSTA IMMUNITARIA IN PAZIENTI RESISTENTI AL TRATTAMENTO STANDARD NEL CARCINOMA RENALE METASTATICO (mRCC) - studio “TRANSLATE - rene”

Ongoing
2
28
Europe
ENDOXAN, proleukin, Coated tablet, Powder for solution for injection, ENDOXAN BAXTER - 50 MG COMPRESSE RIVESTITE 50 COMPRESSE, PROLEUKIN - INIETTABILE 1 FLAC 18.000.000 UI 1 ML
AZIENDA SANITARIA OSPEDALIERA S.CROCE E CARLE CUNEO, Rete Oncologica del Piemonte e valle d'Aosta
metastatic renal cell carcinoma (mRCC) CARCINOMA RENALE METASTATICO, metastatic renal cell carcinoma (mRCC) CARCINOMA RENALE METASTATICO, Diseases [C] - Cancer [C04]
 
 
2016-000579-26: RESTORE IMMUNE COMPETENCE AGAINST CANCER CELLS IN PROSTATE CARCINOMA RESISTANT TO STANDARD TREATMENTS TRANSLATE – prostate STUDY ATTIVAZIONE DELLA RISPOSTA IMMUNITARIA IN PAZIENTI RESISTENTI AL TRATTAMENTO STANDARD - studio “TRANSLATE - prostata”

Ongoing
2
28
Europe
Endoxan, PROLEUKIN, Coated tablet, Powder for solution for injection, ENDOXAN BAXTER - 50 MG COMPRESSE RIVESTITE 50 COMPRESSE, PROLEUKIN - INIETTABILE 1 FLAC 18.000.000 UI 1 ML
AZIENDA SANITARIA OSPEDALIERA S.CROCE E CARLE CUNEO, RETE ONCOLOGICA DEL PIEMONTE E VALLE D'AOSTA
metastatic castration resistant prostate carcinoma (mCRPC) carcinoma della prostata metastatico resistente alla castrazione (mCRPC), metastatic castration resistant prostate carcinoma (mCRPC) carcinoma della prostata metastatico resistente alla castrazione (mCRPC), Diseases [C] - Cancer [C04]
 
 
NCT02340676: A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD

Active, not recruiting
2
25
US
Extracorporeal Photopheresis (ECP), Interleukin-2, IL-2, Proleukin®
Dana-Farber Cancer Institute, Prometheus Laboratories
Chronic Graft-versus-host-disease
08/17
12/25
2017-002126-20: Aldesleukin Therapy in Type 1 Diabetes

Ongoing
2
45
Europe
Aldesleukin, Aldesleukin, Solution for injection in pre-filled pen, Proleukin
University of Oxford, JDRF
Type 1 Diabetes, Type 1 Diabetes, Diseases [C] - Immune System Diseases [C20]
 
 
NCT02748564: Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

Terminated
2
10
US
Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2, Laboratory Biomarker Analysis, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
Rutgers, The State University of New Jersey, National Cancer Institute (NCI)
Metastatic Melanoma, Stage III Mucosal Melanoma of the Head and Neck, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Skin Melanoma, Stage IVA Mucosal Melanoma of the Head and Neck, Stage IVB Mucosal Melanoma of the Head and Neck, Stage IVC Mucosal Melanoma of the Head and Neck
10/18
06/23
2018-003635-30: NA Traitement par IL2 à faible dose chez des femmes ayant des fausses couches spontanées précoces répétées inexpliquées

Not yet recruiting
2
10
Europe
Proleukin, L03A-CO1, Powder for concentrate for solution for injection/infusion, Proleukin
ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP), ANR
NA Femmes ayant des fausses couches spontanées précoces répétées inexpliquées (FCRI), NA Femmes ayant des fausses couches spontanées précoces répétées inexpliquées (FCRI), Diseases [C] - Immune System Diseases [C20]
 
 
NCT02964078: Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer

Active, not recruiting
2
27
US
Pembrolizumab, anti-PD-1 antibody, Keytruda™, Interleukin-2, aldesleukin, Proleukin™, IL-2
H. Lee Moffitt Cancer Center and Research Institute, Merck Sharp & Dohme LLC, Prometheus Laboratories
Kidney Cancer
03/19
10/25
NCT04135092: Single Patient Protocol: A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab

No Longer Available
2
NA
Individual Patient TCR Transduced PBL, Cyclophosphamide, Fludarabine, Aldesleukin, Pembrolizumab
National Institutes of Health Clinical Center (CC)
 
 
NCT03850691: Radiation and Combination Immunotherapy for Melanoma

Completed
2
4
US
Aldesleukin: All Patients, IL-2, Nivolumab: Cohort 1 (Cutaneous), Nivolumab: Cohort 2 (Ocular), Ipilimumab: Cohort 2 (Ocular)
Masonic Cancer Center, University of Minnesota
Metastatic Melanoma
05/21
12/22
2020-003629-45: A clinical study to investigate if the investigational product, called LN -145 (also known as Tumor Infiltrating Lymphocytes) is safe and beneficial in the treatment of patients with Metastatic Non-Small-Cell Lung Cancer

Not yet recruiting
2
148
Europe
LN-145, Fludarabine Phosphate, Cyclophosphamide Injection, Proleukin, LN-145, Solution for infusion, Concentrate for solution for infusion, Powder for solution for infusion, Powder for solution for injection, Powder for solution for injection/infusion, Fludarabine Phosphate, Cyclophosphamide, Proleukin
Iovance Biotherapeutics, Inc., Iovance Biotherapeutics, Inc.
Metastatic Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Diseases [C] - Cancer [C04]
 
 
NCT01659151: Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma

Active, not recruiting
2
17
US
High Dose Interleukin-2 (IL-2), aldesleukin, Proleukin, ACT with TIL Infusion, Vemurafenib, Zelboraf, B-Raf enzyme inhibitor, Lymphodepletion, fludarabine, Fludara, cyclophosphamide, Neostar, Cytoxan
H. Lee Moffitt Cancer Center and Research Institute
Metastatic Melanoma
10/21
09/25
NCT01857934: Therapy for Children With Advanced Stage Neuroblastoma

Active, not recruiting
2
153
US
cyclophosphamide, Cytoxan(R), topotecan, Hycamtin(R), hu14.18K322A, humanized anti-GD2 antibody, monoclonal antibody, dinutuximab, peripheral blood stem cell harvest, PBSCH, surgical resection, cisplatin, Platinol-AQ(R), etoposide, VP16, Vepesid(R), Etopophos(R), doxorubicin, Adriamycin(R), vincristine, Oncovin(R), busulfan, Busulfex(R), melphalan, L-phenylalanine mustard, Phenylalanine mustard, L-PAM, L-sarcolysin, Alkeran(R), peripheral blood stem cell transplantation, PBSCT, natural killer cell infusion, NK cell infusion, radiation therapy, GM-CSF, sargramostim, Leukine(R), granulocyte macrophage colony stimulating factor, G-CSF, Granulocyte colony stimulating factor, Neupogen(R), Filgrastim, mesna, Mesnex(R), levetiracetam, Keppra, interleukin-2, IL-2, aldesleukin, Proleukin(R), Isotretinoin, 13-cis retinoic acid, CliniMACS, Cell Selection System
St. Jude Children's Research Hospital, Cookies for Kids' Cancer, CURE Childhood Cancer, Inc.
Neuroblastoma
10/21
12/25
ITAD, NCT03782636: Interleukin-2 Therapy of Autoimmunity in Diabetes

Active, not recruiting
2
41
Europe
Aldesleukin, Placebo
University of Oxford, Oxford Clinical Trials Research Unit (OCTRU), Centre for Statistics in Medicine, Oxford, JDRF, Wellcome
Type1 Diabetes
04/22
09/22
NCT04383067: A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients

Recruiting
2
20
RoW
Tumor Infiltrating Lymphocytes (TIL), Proleukin
Sheba Medical Center
Metastatic Urothelial Carcinoma
06/22
06/23
NCT00534469: Auto BMT for Non-M3 AML in 1st Remission in Pts

Active, not recruiting
2
60
NA
aldesleukin, Proleukin, filgrastim, Neupogen, busulfan, Myleran, Busulfex IV, cytarabine, cytosine arabinoside, ara-C, arabinofuranosyl cytidine, Cytosar-U, etoposide, VP-16, Vepesid, Toposar, Etophosphos, idarubicin, Idamycin, Zavedos, 4-demethoxydaunorubicin, autologous hematopoietic stem cell transplantation, bone marrow transplantation, peripheral blood stem cell transplantation, total-body irradiation
City of Hope Medical Center, National Cancer Institute (NCI)
Leukemia
12/22
08/25
NCT03501381: High Dose IL 2 and Entinostat in RCC

Active, not recruiting
2
46
US
Entinostat, Interleukin-2, aldesleukin
Roberto Pili, Indiana University Melvin and Bren Simon Cancer Center, Syndax Pharmaceuticals, Clinigen, Inc.
Renal Cell Carcinoma
01/23
04/24
NCT01697527: Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies

Active, not recruiting
2
6
US
aldesleukin, IL-2, Proleukin, recombinant human interleukin-2, recombinant interleukin-2, fludarabine phosphate, 2-F-ara-AMP, Beneflur, Fludara, cyclophosphamide, CPM, CTX, Cytoxan, Endoxan, Endoxana, laboratory biomarker analysis, NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL, anti-NY-ESO-1 TCR gene-engineered lymphocytes, anti-NY-ESO-1 TCR retroviral vector-transduced lymphocytes, dendritic cell vaccine therapy, fludeoxyglucose F 18, 18FDG, FDG, positron emission tomography, FDG-PET, PET, PET scan, tomography, emission computed
Jonsson Comprehensive Cancer Center
Malignant Neoplasm
11/25
11/26
NCT02306954: Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer

Active, not recruiting
2
84
US
High Dose IL-2, Proleukin, SBRT
Providence Health & Services, Prometheus Laboratories, Cytokine Working Group
Renal Cell Carcinoma
09/20
12/26
NCT01174121: Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

Recruiting
2
332
US
Pembrolizumab (Keytruda), Fludarabine, Cyclophosphamide, Aldesleukin, Young TIL
National Cancer Institute (NCI)
Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Metastatic Ovarian Cancer, Metastatic Breast Carcinoma, Metastatic Endocrine Tumors/ Neuroendocrine Tumors
12/28
12/29
NCT02027935: CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma

Completed
2
16
US
Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2, Autologous CD8+ Melanoma Specific T Cells, Autologous Melanoma Specific Cytotoxic T Lymphocytes, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Laboratory Biomarker Analysis
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Metastatic Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7
04/24
04/24
NCT01319565: Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...

Completed
2
102
US
Aldesleukin, Cyclophosphamide, Fludarabine, Young TIL, Total Body Irradiation (TBI)
National Cancer Institute (NCI)
Metastatic Melanoma, Skin Cancer
09/24
09/24
NCI-2018-00918, NCT03449108: LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

Active, not recruiting
2
30
US
Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2, Autologous Tumor Infiltrating Lymphocytes LN-145, Autologous TILs LN-145, Autologous Tumor-infiltrating Lymphocytes LN-145, LN-145, LN145, Autologous Tumor Infiltrating Lymphocytes LN-145-S1, Autologous TILs LN-145-S1, Autologous Tumor-infiltrating Lymphocytes LN-145-S1, LN 145-S1, LN-145-S1, LN145-S1, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine, Fluradosa, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
M.D. Anderson Cancer Center, Iovance Biotherapeutics, Inc., National Cancer Institute (NCI)
Bone Sarcoma, Dedifferentiated Chondrosarcoma, Giant Cell Tumor of Bone, Malignancy in Giant Cell Tumor of Bone, Malignant Solid Neoplasm, Ovarian Carcinosarcoma, Platinum-Resistant Ovarian Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Osteosarcoma, Recurrent Ovarian Carcinoma, Refractory Osteosarcoma, Soft Tissue Sarcoma, Thyroid Gland Anaplastic Carcinoma, Thyroid Gland Squamous Cell Carcinoma, Undifferentiated High Grade Pleomorphic Sarcoma of Bone, Triple Negative Breast Cancer
04/27
04/27
NCT04562129: IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

Recruiting
2
29
US
Interleukin-2, Aldesleukin, Ipilimumab, Nivolumab
H. Lee Moffitt Cancer Center and Research Institute, Clinigen, Inc.
Melanoma Stage III, Melanoma Stage IV, Inoperable Disease
08/25
11/29
NCT02133196: T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

Recruiting
2
85
US
Aldesleukin, Fludarabine, Cyclophosphamide, Young TIL
National Cancer Institute (NCI)
Advanced Non-Small Cell Lung Cancer, Squamous Cell Carcinoma, Advanced NSCLC, Adenosquamous Carcinoma, Adenocarcinoma
10/25
10/25
NCT05754684: Quadruple Immunotherapy for Neuroblastoma

Recruiting
2
29
RoW
Natural killer cell, NK cell, Dinutuximab beta, Ch14.18, Interleukin-2, Aldesleukin, Granulocyte-Macrophage Colony-Stimulating Factor, Sargramostim, Spironolactone, Aldactone, Naxitamab, hu3F8
Hong Kong Children's Hospital, The University of Hong Kong
Neuroblastoma Recurrent
12/24
12/25
NCT05686226: E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

Recruiting
2
20
US
E7 TCR-T cells, E7 TCR, HPV TCR, TIL, Adoptive cell transfer, CAR-T, TCR, Aldesleukin, Proleukin
Christian Hinrichs, National Cancer Institute (NCI), Iovance Biotherapeutics, Inc.
Cervical Cancer, Throat Cancer, Oropharynx Cancer, Anal Cancer, Vulva Cancer, Vaginal Cancer, Penile Cancer, Metastatic Cancer, HPV-Related Malignancy, HPV-Related Carcinoma, HPV-Related Cervical Carcinoma, HPV-Related Squamous Cell Carcinoma, HPV-Related Adenocarcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Associated Vaginal Adenocarcinoma, HPV-Related Adenosquamous Carcinoma, HPV-Related Endocervical Adenocarcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, HPV Positive Rectal Squamous Cell Carcinoma
01/27
01/27
NCT02621021: A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab

Recruiting
2
170
US
young TIL, Pembrolizumab, Aldesleukin, Fludarabine, Cyclophosphamide
National Cancer Institute (NCI)
Melanoma
06/28
06/29
NCT06690281: A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies

Recruiting
2
65
US
KRAS TCR-Transduced PBL, Aldesleukin, Fludarabine, Cyclophosphamide
National Cancer Institute (NCI)
Gastrointestinal Carcinoma, Pancreatic Cancer, Hepatocellular Cancer, Cholangiocarcinoma, Duodenal Cancer, Colorectal Cancer, Small Bowel Cancer, Metastatic Cancers
06/29
06/33
DTIC, NCT00553618: Adjuvant, Combined Interleukin 2 (Proleukin) and (Dacarbazine) in High-risk Melanoma Patients

Active, not recruiting
2
160
US
Proleukin and Dacarbazine, Proleukin, Dacarbazine
University of Louisville, James Graham Brown Cancer Center
Metastatic Melanoma
08/25
08/26
NCT05155033: Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

Recruiting
2
78
US
Pembrolizumab, Aldesleukin
National Cancer Institute (NCI)
Metastatic Melanoma, Advanced Locoregional Melanoma, Metastatic Renal Cell Carcinoma, Clear Cell Histology
09/26
09/27
NCT03412877: Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

Recruiting
2
270
US
Cyclophosphamide, Fludarabine, Aldesleukin, Individual Patient TCR-Transduced PBL, Pembrolizumab (KEYTRUDA(R))
National Cancer Institute (NCI)
Endocrine Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer, Gastrointestinal/Genitourinary Cancers, Neuroendocrine Tumors, Multiple Myeloma
03/27
03/28
NCT04102436: Non-Viral TCR Gene Therapy

Withdrawn
2
210
US
Fludarabine, Cyclophosphamide, Aldesleukin, Sleeping Beauty Transposed PBL
National Cancer Institute (NCI)
Endocrine/Neuroendocrine, Non-Small Cell Lung Cancer, Breast Cancer, Gastrointestinal/Genitourinary Cancers, Ovarian Cancer
03/24
03/24
NCT00338377: Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma

Active, not recruiting
2
1230
US
Dendritic Cell Immunization, Cyclophosphamide, Cytoxan, Neosar, Fludarabine, Fludarabine Phosphate, Fludara, T-Cells, Interleukin-2, IL-2, Proleukin, Mesna, Sodium 2-mercaptoethanesulfonate, Mesnum, Mesnex, NSC-113891, Intrathecal T-Cells, Intrathecal Interleukin-2
M.D. Anderson Cancer Center, Prometheus Laboratories, Key Biologics, LLC, National Cancer Institute (NCI), Adelson Medical Research
Melanoma
02/30
02/30
2016-003578-42: Infusion of activated NK cells for the treatment of children, adolescents and young adults with sarcomas. Infusión de células NK activadas para el tratamiento de niños, adolescentes y adultos jóvenes con sarcomas.

Ongoing
1/2
10
Europe
NK cells, Proleukin, Injection, Powder for solution for injection/infusion, PROLEUKIN
Antonio Pérez-Martínez, Servicio de Hemato-Oncología Infantil. Hospital Universitario La Paz.
Sarcoma Sarcoma, Sarcoma Sarcoma, Diseases [C] - Cancer [C04]
 
 
NCT01038778: Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer

Active, not recruiting
1/2
47
US
Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Entinostat, HDAC inhibitor SNDX-275, MS 27-275, MS 275, MS-275, MS275, SNDX 275, SNDX-275, SNDX275, Fludeoxyglucose F-18, 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Laboratory Biomarker Analysis, Pharmacological Study, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT
National Cancer Institute (NCI)
Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
05/19
02/26
2021-005110-34: ICT01 in combination with IL-2 in patients with advanced solid tumors

Not yet recruiting
1/2
42
Europe
ICT01, proleukin, Solution for infusion, Powder for solution for injection, PROLEUKIN®
ImCheck Therapeutics, Inc., ImCheck Therapeutics, Inc.
Relapsed/refractory patients with advanced solid tumors : metastatic colorectal cancer (CRC) or metastatic ovarian cancer or metastatic castration-resistant prostate cancer (mCRPC) or metastatic pancreatic ductal adenocarcinoma (PDAC), Relapsed/refractory patients with metastatic cancer : colorectal or ovarian or prostate or pancreatic ductal adenocarcinoma, Diseases [C] - Cancer [C04]
 
 
NCT05207722: CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

Terminated
1/2
1
US
CYNK-101, Pembrolizumab, Keytruda®, Trastuzumab, Herceptin®, Recombinant Human Interleukin-2, proleukin, Cyclophosphamide, cytoxan, Fludarabine, fludara, Mesna
Celularity Incorporated
Metastatic HER2 Positive Gastroesophageal Junction Cancer
02/24
02/24
NCI-2014-02655, NCT01740557: Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma

Completed
1/2
10
US
Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2, CXCR2-transduced Autologous Tumor Infiltrating Lymphocytes, CXCR2-transduced Autologous TILs, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, Laboratory Biomarker Analysis, NGFR-transduced Autologous T Lymphocytes, Quality-of-Life Assessment, Quality of Life Assessment
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
04/23
04/23
2019LS002, NCT04426669: A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering

Active, not recruiting
1/2
20
US
Cyclophosphamide, Fludarabine, Tumor-Infiltrating Lymphocytes (TIL), Aldesleukin, Interleukin-2, IL-2
Intima Bioscience, Inc., Masonic Cancer Center, University of Minnesota
Gastrointestinal Epithelial Cancer, Gastrointestinal Neoplasms, Cancer of Gastrointestinal Tract, Cancer, Gastrointestinal, Gastrointestinal Cancer, Colo-rectal Cancer, Pancreatic Cancer, Gall Bladder Cancer, Colon Cancer, Esophageal Cancer, Stomach Cancer
01/26
01/26
NK4AML, NCT04347616 / 2019-001929-27: Natural Killer-cell Therapy for Acute Myeloid Leukemia

Recruiting
1/2
23
Europe
UCB-NK cells, IL-2, Aldesleukin
Radboud University Medical Center, Dutch Cancer Society
Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, Relapsed, Adult
09/25
09/25
NCT03318900: T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer

Completed
1/2
5
US
Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2, CD8-Positive T-Lymphocyte, CD8 Cell, CD8 Lymphocyte, CD8 Lymphocytes, CD8+ T Cell, CD8+ T Lymphocyte, CD8+ T Lymphocytes, CD8+ T-Lymphocyte, CD8-Positive Lymphocyte, CD8-Positive Lymphocytes, CD8-Positive T-Lymphocytes, T8 Cell, T8 Cells, T8 Lymphocyte, T8 Lymphocytes, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Leukapheresis, Leukocytopheresis, Therapeutic Leukopheresis, Utomilumab, PF 05082566, PF 5082566, PF-05082566, PF-2566
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
COL6A3 Positive, HLA-A*0201 Positive Cells Present, PRAME Positive, Recurrent Ovarian Carcinoma
12/23
12/23
NCT03658785: Immunotherapy for the Treatment of Advanced Solid Tumor

Recruiting
1/2
40
RoW
TIL, Aldesleukin, IL-2, Cyclophosphamide, CTX, Fludarabine
Tongji Hospital
Recurrence Tumor, Metastatic Cancer, Solid Tumor
12/24
12/25
EVICTION-2, NCT05307874 / 2021-005110-34: Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid Tumors

Active, not recruiting
1/2
56
Europe
ICT01, Proleukin Injectable Product, IL-2, Pembrolizumab injection
ImCheck Therapeutics, ILife Consulting, Exystat
Solid Tumor, Adult
09/25
12/25
NCT05821686: Efficacy of Interleukin-2 in Triple Negative Breast Cancer

Not yet recruiting
1/2
10
NA
Human Interleukin-2 (IL-2) (Proleukin)
Nova Scotia Health Authority
Triple Negative Breast Cancer
04/28
04/28
NCT05267626: Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Recruiting
1/2
159
US, RoW
AU-007, Aldesleukin, Avelumab, Nivolumab
Aulos Bioscience, Inc.
Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer
08/25
09/25
NCT04089891: A Study in Patients With Metastatic Gastrointestinal Epithelial Cancer Administering Tumor-Infiltrating Lymphocytes in Which the Gene Encoding CISH Was Inactivated Using the CRISPR/Cas9 System

Not yet recruiting
1/2
41
NA
Lymphodepleting Chemotherapy Regimen, Tumor-Infiltrating Lymphocytes (TIL), Aldesleukin
Masonic Cancer Center, University of Minnesota
Gastrointestinal Epithelial Cancer
10/24
10/24
CheckCell-2, NCT05566223: CISH Inactivated TILs in the Treatment of NSCLC

Not yet recruiting
1/2
70
US
Fludarabine, Fludara, Cyclophosphamide, Cytoxan, CISH Inactivated TIL, Aldesleukin, Proleukin, Interleukin-2, IL-2, Pembrolizumab, Keytruda
Intima Bioscience, Inc.
Carcinoma, Non-Small-Cell Lung, Metastatic Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Adenocarcinoma of Lung, Large Cell Lung Cancer
11/25
11/27
NCT05194735: Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors

Active, not recruiting
1/2
180
US
Neoantigen specific TCR-T cell drug product, Aldesleukin (IL-2)
Alaunos Therapeutics
Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer, Non-small Cell Lung Cancer, Cholangiocarcinoma, Ovarian Cancer, Endometrial Cancer, Ovarian Carcinoma, Ovary Neoplasm, Squamous Cell Lung Cancer, Adenocarcinoma of Lung, Adenosquamous Cell Lung Cancer
11/24
11/24
Indapta-Trial-1, NCT06119685: IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Recruiting
1/2
128
US
IDP-023, Rituximab, Rituxan, Daratumumab, Darzalex, Interleukin-2, Proleukin, Cyclophosphamide, Fludarabine, Mesna, Isatuximab, Sarclisa
Indapta Therapeutics, INC.
NHL, Multiple Myeloma, Blood Cancer, Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma
12/25
12/29
NCT02858310: E7 TCR T Cells for Human Papillomavirus-Associated Cancers

Recruiting
1/2
180
US
E7 TCR cells, Aldesleukin, Fludarabine, Cyclophosphamide
National Cancer Institute (NCI)
Papillomavirus Infections, Cervical Intraepithelial Neoplasia, Carcinoma In Situ, Vulvar Neoplasms, Vulvar Diseases
12/25
01/26
NCT05639972: E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

Recruiting
1/2
15
US
E7 TCR-T cells, E7 TCR, HPV TCR, TIL, Adoptive cell transfer, CAR-T, TCR, Aldesleukin, Proleukin
Christian Hinrichs, Iovance Biotherapeutics, Inc.
HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma, HPV-Related Malignancy, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Adenocarcinoma, HPV-Related Adenosquamous Carcinoma, HPV-Related Squamous Cell Carcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, HPV-Related Endocervical Adenocarcinoma, Cervical Cancer, Oropharynx Cancer, Anal Cancer, Vulvar Cancer, Penile Cancer, Vaginal Cancer
10/26
10/26
NCT02830724: Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

Recruiting
1/2
124
US
Cyclophosphamide, Fludarabine, Aldesleukin, Anti-hCD70 CAR transduced PBL
National Cancer Institute (NCI)
Pancreatic Cancer, Renal Cell Cancer, Breast Cancer, Melanoma, Ovarian Cancer
01/27
01/28
NCT03190941 / 2017-000268-14: Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

Recruiting
1/2
110
US
Cyclophosphamide, Fludarabine, Anti-KRAS G12V mTCR PBL, Aldesleukin
National Cancer Institute (NCI)
Pancreatic Cancer, Gastric Cancer, Gastrointestinal Cancer, Colon Cancer, Rectal Cancer
06/27
06/28
19-C-0017, NCT03745326: Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

Recruiting
1/2
70
US
Cyclophosphamide, Fludarabine, Aldesleukin, anti-KRAS G12D mTCR PBL
National Cancer Institute (NCI)
Gastrointestinal Cancer, Pancreatic Cancer, Gastric Cancer, Colon Cancer, Rectal Cancer
12/27
12/28
NCT05296564: Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers

Recruiting
1/2
3
RoW
CYCLOPHOSPHAMIDE and FLUDARABIN, CYTOXAN, Cyclophosphamide, HBI 0201-ESO TCRT, Aldesleukin, Interleukin-2
Hadassah Medical Organization
Sarcoma, Synovial, Sarcoma,Soft Tissue, Melanoma Stage IV, Triple Negative Breast Cancer, Metastatic Cancer, Non Small Cell Lung Cancer, Bladder Urothelial Carcinoma, Neuroblastoma, Metastatic, Ovary Cancer
12/27
12/27
NCT01909206: A Phase I Trial of Anti-PD-1, Anti-CD137 and TIL

Not yet recruiting
1
24
US
Nivolumab, Anti-PD-1 blocking antibody, BMS-936558, Tumor Infiltrating Lymphocyte (TIL), Cyclophosphamide, Cytoxan, Mesna, Sodium 2-mercaptoethanesulfonate, Mesnum, Mesnex, NSC-113891, Fludarabine, Fludara, TIL Infusion, High Dose Interleukin-2 (IL-2), Aldesleukin, Proleukin
H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb, Prometheus Laboratories, National Cancer Institute (NCI)
Metastatic Melanoma
12/16
12/16
NCT03017131: Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Active, not recruiting
1
9
US
Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Decitabine, 5-Aza-2'-deoxycytidine, Dacogen, Decitabine for Injection, Deoxyazacytidine, Dezocitidine, Genetically Engineered NY-ESO-1-specific T Lymphocytes, Laboratory Biomarker Analysis
Roswell Park Cancer Institute, National Cancer Institute (NCI)
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
03/20
03/32
NCI-2018-01758, NCT03691376: Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Terminated
1
4
US
Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, recombinant human interleukin-2, Autologous NY-ESO-1-specific CD8-positive T Lymphocytes, Cellular Therapy, Cell Therapy, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalanum, Phenylalanine Mustard, Phenylalanine nitrogen mustard, Sarcoclorin, Sarkolysin, WR-19813
Roswell Park Cancer Institute
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Platinum-Sensitive Fallopian Tube Carcinoma, Platinum-Sensitive Ovarian Carcinoma, Platinum-Sensitive Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Refractory Fallopian Tube Carcinoma, Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Carcinoma
01/21
06/24
CA209-9JA, NCT03215810: Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer

Completed
1
20
US
Tumor-infiltrating Lymphocytes (TIL), TIL, Nivolumab, Opdivo, Cyclophosphamide, Cytoxan, Fludarabine, Fludara, Tumor-infiltrating Lymphocyte Therapy, Interleukin-2 (IL2), IL2, Proleukin®
H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb, Prometheus Inc., Stand Up To Cancer, Iovance Biotherapeutics, Inc.
Non-Small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, Squamous Cell Carcinoma, Advanced NSCLC, Adenosquamous Carcinoma, Adenocarcinomas
02/21
06/23
NCT06307301: Study in ALS With Abatacept & IL-2

Active, not recruiting
1
5
US
Abatacept Injection [Orencia] and Proleukin (aldesleukin)
The Methodist Hospital Research Institute
Amyotrophic Lateral Sclerosis
10/24
10/24
NCT05821153: Low Dose IL2 Immunotherapy in AD

Completed
1
8
US
Aldesleukin
The Methodist Hospital Research Institute
Alzheimer Disease
04/22
04/22
NCT04545827: Study to Evaluate the Safety of IMM-01 in Patients With Advanced Solid Tumours

Not yet recruiting
1
10
NA
IMM-01, Losartan, Proleukin
Modulate Therapeutics Ltd
Solid Tumor, Solid Carcinoma, Neoplasms, Uveal Melanoma, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Car. - Esophagus, Renal Cell Carcinoma, Colorectal Cancer, Advanced Cancer
07/22
07/22
NCT03260504: Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer

Terminated
1
6
US
Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Immunoglobulin G4, Anti-(Human Programmed Cell Death 1)
University of Washington, Merck Sharp & Dohme LLC, Prometheus Laboratories
Advanced Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Metastatic Clear Cell Renal Cell Carcinoma
07/22
07/22
NCI-2018-00926, NCT03450122: Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma

Checkmark Initiation of pivotal monotherapy trial
Mar 2018 - Mar 2018: Initiation of pivotal monotherapy trial
Completed
1
15
US
Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2, Autologous NY-ESO-1-specific CD8-positive T Lymphocytes, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Dendritic Cell-targeting Lentiviral Vector ID-LV305, DCvex-NY-ESO-1, ID-LV305
M.D. Anderson Cancer Center
HLA-A*0201 Positive Cells Present, NY-ESO-1 Positive Tumor Cells Present, Recurrent Myxoid Liposarcoma, Recurrent Synovial Sarcoma
12/22
12/22
NCT03068624: Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

Active, not recruiting
1
34
US
Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2, Autologous CD8+ SLC45A2-specific T Lymphocytes, Autologous SLC45A2-specific CTLs, Autologous SLC45A2-specific Cytotoxic T Lymphocytes, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma
12/22
07/25
NCT04551885: FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Terminated
1
12
US
FT516, Avelumab, Bavencio, Cyclophosphamide, Fludarabine, IL-2, Proleukin, Aldesleukin
Fate Therapeutics
Solid Tumor, Adult
08/23
08/23
NCT05483491: KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer

Recruiting
1
30
US
KK-LC-1 TCR-T cells, KK-LC-1 TCR, TIL, Adoptive cell transfer, CAR-T, TCR, Aldesleukin, Proleukin
Christian Hinrichs, National Cancer Institute (NCI), Iovance Biotherapeutics, Inc.
Gastric Cancer, Breast Cancer, Cervical Cancer, Lung Cancer
09/26
12/28
NYESO SCT, NCT03240861: Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer

Terminated
1
5
US
18F-FHBG, Reporter Probe 18F-FHBG, Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2, Busulfan, 1, 4-Bis[methanesulfonoxy]butane, BUS, Bussulfam, Busulfanum, Busulfex, Busulphan, CB 2041, CB-2041, Glyzophrol, GT 41, GT-41, Joacamine, Methanesulfonic Acid Tetramethylene Ester, Methanesulfonic acid, tetramethylene ester, Mielucin, Misulban, Misulfan, Mitosan, Myeleukon, Myeloleukon, Myelosan, Mylecytan, Myleran, Sulfabutin, Tetramethylene Bis(methanesulfonate), Tetramethylene bis[methanesulfonate], WR-19508, Cellular Therapy, Cell Therapy, Computed Tomography, CAT, CAT Scan, Computerized Axial Tomography, Computerized Tomography, CT, CT SCAN, tomography, Filgrastim, Filgrastim XM02, Filgrastim-sndz, G-CSF, Granix, Neupogen, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, rG-CSF, Tbo-filgrastim, Tevagrastim, Zarxio, Fludarabine, Fluradosa, Leukapheresis, Leukocytopheresis, Therapeutic Leukopheresis, Plerixafor, AMD 3100, JM-3100, Mozobil, SDZ SID 791, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET SCAN, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging
Jonsson Comprehensive Cancer Center, California Institute for Regenerative Medicine (CIRM)
HLA-A*0201 Positive Cells Present, Locally Advanced Malignant Neoplasm, NY-ESO-1 Positive, Unresectable Malignant Neoplasm, Sarcoma
10/23
10/23
NCT06138587: Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation

Recruiting
1
15
US
Cytokine Induced Memory-like Natural Killer Cells, CIML NK cells, Interleukin-2, Aldesleukin, Proleukin
Dana-Farber Cancer Institute
Acute Myeloid Leukemia, Leukemia, Leukemia, Myeloid, Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Myeloproliferative Disorders
02/26
11/26
NCT06152809: CIML NK Cells With Venetoclax for AML

Recruiting
1
10
US
Cytokine-Induced Memory-like Natural Killer Cells, CIML NK Cells, Interleukin-2, Aldesleukin, Proleukin, IL-2, Venetoclax, C45H50ClN7O7S
Dana-Farber Cancer Institute, The Leukemia and Lymphoma Society
Acute Myeloid Leukemia, Acute Myeloid Leukemia Recurrent, Leukemia, Leukemia, Myeloid
11/26
11/27
NCT06236425: TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC

Active, not recruiting
1
7
US
TBio-4101, Tumor-Infiltrating Lymphocyte, Pembrolizumab, Keytruda, Platinum based chemotherapy, Cisplatin, Carboplatin/5-FU, Cyclophosphamide, Cytoxan, Fludarabine, Fludara, Aldesleukin, Interleukin-2, IL-2
H. Lee Moffitt Cancer Center and Research Institute, Turnstone Biologics, Corp.
Squamous Cell Carcinoma of Head and Neck, Metastatic Squamous Cell Carcinoma
08/26
08/26
NCT01590069: Aerosolized Aldesleukin in Treating Patients With Lung Metastases

Active, not recruiting
1
70
US
Aerosolized Aldesleukin, Aerosolized Recombinant IL-2, Laboratory Biomarker Analysis
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Metastatic Malignant Neoplasm in the Lung, Metastatic Melanoma, Metastatic Osteosarcoma, Metastatic Renal Cell Cancer, Sarcoma, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Osteosarcoma AJCC v7, Stage IV Renal Cell Cancer AJCC v7
04/26
04/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Actimmune (interferon gamma-1 b) / Clinigen, Amgen
2012-002491-14: The effects of the drug interferon-gamma on suppression of the immune system in patients with sepsis De effecten van het geneesmiddel interferon-gamma op onderdrukking van het immuunsysteem veroorzaakt door sepsis.

Ongoing
3
20
Europe
Recombinant human interferon-gamma, L03A B03, Immukine, Immukine
Radboud University Nijmegen Medical Centre, Radboud University Nijmegen Medical Centre
Sepsis-induced immunoparalysis (SIRS, Sepsis, Septic shock) Sepsis geïnduceerde immuunparalyse
 
 
2015-002432-40: Safety and Efficacy of yIFN treatment in Friedreich ataxia Sicurezza ed efficacia del trattamento con Interferone gamma (¿IFN) nell'Atassia di Friedreich

Not yet recruiting
2
12
Europe
Imukin, Solution for injection, IMUKIN - 6 FLACONI 0.5 ML 100 MCG
ASSOCIAZIONE "LA NOSTRA FAMIGLIA" - SEZIONE SCIENTIFICA I.R.C.C.S. "E.MEDEA", Associazione di pazienti
FRDA is a progressive neurodegenerative disease inherited as recessive trait. It manifests itself usually in adolescence and affects various systems including the central and peripheral nervous system (balance, coordination, speech and sensitivity), the heart with hypertrophic cardiomyopathy, the bones with skeletal deformities (scoliosis, claw foot) and in some cases diabetes mellitus. The disease causes severe and progressive disability, significantly reducing the life expectancy of patients. FRDA ¿ una malattia neurodegenerativa a carattere progressivo trasmessa in forma autosomica recessiva. Esordisce in particolare in et¿ adolescenziale e colpisce vari sistemi tra cui il nervoso centrale e periferico (disturbi dell¿equilibrio, coordinazione, disturbi del linguaggio e della sensibilit¿), il cuore con cardiomiopatia ipertrofica, le ossa con deformit¿ scheletriche (scoliosi, piede cavo) ed in alcuni casi diabete mellito. La malattia causa disabilit¿ severa e progressiva, riduce in mo, FRDA is a progressive neurodegenerative disease inherited as recessive trait. The disease manifests itself usually in adolescence FRDA ¿ una malattia neurodegenerativa a carattere progressivo che viene trasmessa in forma autosomica recessiva. La malattia esordisce in particolare in et¿ adolescenziale., Diseases [C] - Nervous System Diseases [C10]
 
 
NCT03063632: Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma

Completed
2
28
US
Interferon Gamma-1b, Actimmune, gamma Interferon 1B, IFN-g-1b, IFN-gamma 1b, IFNg-1b, Interferon gamma-1b, Recombinant, N(Sup 2)-L-Methionyl-1-139-Interferon G, N(sup 2)-L-Methionyl-1-139-interferon gamma (Human Lymphocyte Protein Moiety Reduced), Recombinant Interferon Gamma-1b, Laboratory Biomarker Analysis, Pembrolizumab, BCD-201, Keytruda, Lambrolizumab, MK-3475, Pembrolizumab Biosimilar BCD-201, SCH 900475
National Cancer Institute (NCI)
Metastatic Myxoid Liposarcoma, Metastatic Round Cell Liposarcoma, Metastatic Synovial Sarcoma, Recurrent Mycosis Fungoides and Sezary Syndrome, Refractory Mycosis Fungoides and Sezary Syndrome, Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage II Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IVA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v7, Unresectable Synovial Sarcoma
04/21
03/23
PREV-HAP, NCT04793568 / 2020-000620-18: Human Recombinant Interferon Gamma-1b for the Prevention of Hospital-acquired Pneumonia in Critically Ill Patients: a Double-blind, International, Phase 2, Randomized, Placebo-controlled Trial - the Study

Active, not recruiting
2
109
Europe
Recombinant Interferon gamma 1b (IMUKIN®), Recombinant Interferon gamma 1b placebo
Nantes University Hospital
Critically Ill Patients
11/21
06/23
2020-003204-13: Safety and Efficacy of Immunotherapy in Patients With Candidemia Veiligheid en effectiviteit van Immuuntherapie bij patiënten met een uitgebreide schimmelinfectie

Ongoing
2
200
Europe
Immukin, Solution for injection, Immukin
Radboudumc, Hellenic Institute for the Study of Sepsis, Radboudumc, Hellenic Institute for the Study of Sepsis
Candidemia Candidemie, Systemic fungal infection Systemische schimmelinfectie, Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
ImmunoSep, NCT04990232 / 2020-005768-74: Personalized Immunotherapy in Sepsis

Completed
2
280
Europe
Anakinra or rhIFNγ, Imukin, Kineret, Placebo
Hellenic Institute for the Study of Sepsis
Sepsis
02/24
04/24
NCT06529731: Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation

Recruiting
2
45
US
Interferon gamma-1b, ACTIMMUNE®, Donor Leukocyte Infusion (DLI)
Sawa Ito, MD, Evans MDS Discovery Research Grant, Amgen, FDA Office of Orphan Products Development
Acute Myeloid Leukemia, Myelodysplastic Syndromes
10/27
10/27
NCT04979052: Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia

Recruiting
2
200
Europe, US
Interferon Gamma-1B, Immukin
Radboud University Medical Center, Horizon 2020 - European Commission
Candidemia
06/26
06/26
MCC-18936, NCT03112590: Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer

Completed
1/2
51
US
Interferon-gamma (IFN-γ), Actimmune®, signaling proteins, Paclitaxel, Abraxane®, Trastuzumab, Herceptin®, Pertuzumab, PERJETA®, monoclonal antibody, Post Therapy Surgery
H. Lee Moffitt Cancer Center and Research Institute, Horizon Pharma Ireland, Ltd., Dublin Ireland
Breast Cancer, Breast Cancer, Male, Breast Cancer Female, HER2-positive Breast Cancer
03/21
02/23
ATTAC-MCC, NCT03747484: Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer

Terminated
1/2
7
US
Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR, Autologous CD8+ and CD4+ T-cells transduced with TCR A2-MCC1, FH-MCVA2TCR, FH-MCVA2TCR Autologous CD8+ and CD4+ T-cells Transduced with TCR A2-MCC1, Avelumab, 1537032-82-8, Bavencio, Immunoglobulin G1-lambda1, Anti-(Homo sapiens CD274 (Programmed Death Ligand 1, PDL1, pd-l1, B7 Homolog 1, B7H1)), Homo sapiens Monoclonal Antibody, MSB-0010718C, MSB0010718C, Pembrolizumab, Anti-(Human Programmed Cell Death 1), Keytruda, Lambrolizumab, MK-3475, SCH 900475, Interferon Gamma-1b, 98059-61-1, Actimmune, gamma Interferon 1B, IFN-g-1b, IFN-gamma 1b, Recombinant Interferon Gamma-1b
Fred Hutchinson Cancer Center, National Cancer Institute (NCI), Affini-T Therapeutics, Inc.
Other Skin
01/24
01/24
NCT04628338: IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation

Completed
1
8
US
IFN-γ (interferon gamma-1b) injection, ACTIMMUNE®
Sawa Ito, MD, Horizon Pharma USA, Inc.
Myelodysplastic Syndromes, Myeloid Leukemia, Allogeneic Stem Cell Transplantation
10/23
10/23
Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
2007-006730-33: Estudio de los mecanismos implicados en la recuperación de linfocitos CD4+ propiciada por el tratamiento con Interleuquina 2 en pacientes bajo TARGA efectivo, pero con escasa ganancia de linfocitos CD4+. Papel del cotratamiento con antiinflamatorios no esteroideos.

Ongoing
4
40
Europe
PROLEUKIN 18 millones UI polvo para solución inyectable SC, IBUPROFENO ALTER 600 mg, PROLEUKIN 18 millones UI polvo para solución inyectable SC, IBUPROFENO ALTER 600 mg
Hospital Universitario Virgen del Rocío
Infección crónica por VIH
 
 
NCT00026312: Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma

Active, not recruiting
3
1449
Canada, US, RoW
Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2, Dinutuximab, Ch 14.18UTC, Ch14.18, Dinutuximab Beta, MOAB Ch14.18, monoclonal antibody Ch14.18, Qarziba, Unituxin, Isotretinoin, 13-cis retinoic acid, 13-cis-Retinoate, 13-cis-Retinoic Acid, 13-cis-Vitamin A Acid, 13-cRA, Absorica, Accure, Accutane, Amnesteem, cis-Retinoic Acid, Cistane, Claravis, Isotretinoinum, Isotrex, Isotrexin, Myorisan, Neovitamin A, Neovitamin A Acid, Oratane, Retinoicacid-13-cis, Ro 4-3780, Ro-4-3780, Roaccutan, Roaccutane, Roacutan, Sotret, ZENATANE, Laboratory Biomarker Analysis, Pharmacological Study, Quality-of-Life Assessment, Quality of Life Assessment, Sargramostim, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin
National Cancer Institute (NCI)
Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
01/12
03/26
2006-003746-42: Immunotherapy vs immuno-chemotherapy in patients with metastatic kidney carcinoma

Ongoing
3
210
Europe
PROLEUKIN*EV 1FL 18MUI 5ML, GEMZAR*INFUS 1FL 1G POLV, NAVELBINE 50*IV 50MG 5ML, PROLEUKIN*EV 1FL 18MUI 5ML, GEMZAR*INFUS 1FL 1G POLV, NAVELBINE 50*IV 50MG 5ML
OSPEDALE ONCOLOGICO DI BARI
metastatic kidney carcinoma
 
 
2010-020397-42: The efficacy of an antigenic marker lesion for the therapeutic effect in patients with multiple, Ta/T1, G1/G2, non-muscle invasive bladder cancer (NMIBC) treated with TUR followed by IL-2 instillation

Ongoing
3
66
Europe
NA, NA, Proleukin, Proleukin
VUmc Dept Urology
Multiple, Ta / T1, G1 / G2, non-muscle invasive bladder carcinoma
 
 
SIOPEN, NCT01704716: High Risk Neuroblastoma Study 1.8 of SIOP-Europe

Recruiting
3
3300
Europe, RoW
Vincristine, Aldesleukin, Interleukin 2, IL-2, IL2, ch14.18/CHO, anti GD2 antibody, Dinutuximab beta EUSA, Qarziba®, Carboplatin, Paraplatin, Etoposide, VP16, Cisplatin, CDDP, Cyclophosphamide, Endoxan, Doxorubicin, Adriamycin, G-CSF, Filgrastim, Busulfan, Busilvex, Myleran, Busulphan, Melphalan, Alkeran
St. Anna Kinderkrebsforschung
Neuroblastoma
09/21
09/26
NCT02278887 / 2013-005406-54: Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma

Completed
3
168
Europe
Translational research, tumor tissue, blood, Cyclophosphamide, chemotherapy, Fludarabine, Interleukin-2, Proleukin, Ipilimumab infusion, standard treatment
The Netherlands Cancer Institute, Copenhagen University Hospital at Herlev
Metastatic Melanoma
09/22
12/23
NCT03928275: The Response to Intralesional IL-2 and/or BCG Treatment for Cutaneous Metastatic Melanoma

Withdrawn
2/3
100
NA
Interleukin-2, Proleukin (Aldesleukin), Combination therapy Interleukin-2 and Bacillus Calmette Guerin, BCG, strain TICE (OncoTICE) and Proleukin (Aldesleukin)
Carman Giacomantonio, Nova Scotia Health Authority
Cutaneous Metastatic Melanoma
09/22
09/22
Tregs in ALS, NCT04055623: T-regulatory Cells in ALS

Active, not recruiting
2a
12
US
Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections, Individualized therapy Treg cell infusions + Interleukin-2 (IL-2), Proleukin is brand name for IL-2, Monthly placebo infusions + 3 times per week placebo injections, inactive drug, Proleukin is the brand name for IL-2
The Methodist Hospital Research Institute, Massachusetts General Hospital, The Center for Clinical and Translational Sciences (CCTS) Clinical Research Unit at The University of Texas Health Science Center at Houston, North East Amyotrophic Lateral Sclerosis Consortium
ALS (Amyotrophic Lateral Sclerosis)
05/22
08/22
NCT00101101: Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma

Completed
2
43
US
Cyclophosphamide, Cytoxan, Doxorubicin, adriamycin, Rubex, Vincristine, Oncovin, leurocristine, VCR, Prednisone, Deltasone, Liquid Pred, Meticorten, Orasone, Dexamethasone, Decadron, Dexasone, Diodex, Hexadrol, Autologous Tumor Cell-Based Vaccine, IL-2, interleukin-2, cytokine, aldesleukin
H. Lee Moffitt Cancer Center and Research Institute, National Cancer Institute (NCI), Lymphoma Research Foundation, Novartis
Lymphoma
10/12
06/21
2007-002139-94: Multiple dose Phase II study of IPH1101 in monotherapy or associated with a low dose of IL2 (2MIU) in non previously treated hepatitis C patients

Ongoing
2
28
Europe
Phosphostim 200, Proleukin 18 MUI, IPH1101, Proleukin 18MUI, Proleukin 18MUI
Innate Pharma
Non previously treated Hepatitis C patients
 
 
2006-006212-30: A Randomised, Open labelled, Phase II, Immunogenicity, and Exploratory Efficacy Evaluation of Therapeutic Immunisations +/- IL-2, GM-CSF and Growth Hormone in HIV-1 Infected Subjects Receiving Highly Active Anti-retroviral Therapy (HAART).

Ongoing
2
30
Europe
Saizen, IR103, Proleukin, Leukine, IR103 is a combination of Remune and Amplivax, Saizen, Proleukin, Leukine, Saizen, Proleukin, Leukine
Imperial College London
HIV-1
 
 
2007-007265-20: A Phase II open label randomized parallel group non comparative trial to assess efficacy and safety of the association of IPH1101 and IL-2 alone and in combination with dacarbazine, in patients with metastatic melanoma

Ongoing
2
6
Europe
Phosphostim 200, PROLEUKIN 18 MUI, Dacarbazine Mayne 600 mg, IPH1101, DTIC, PROLEUKIN 18 MUI, Dacarbazine Mayne 600 mg, poudre pour solution injectable, PROLEUKIN 18 MUI, Dacarbazine Mayne 600 mg, poudre pour solution injectable
Innate Pharma
metastatic melanoma
 
 
2009-012583-13: Phase II study of interleukin-2 and zoledronic acid as maintenance therapy in patients with multiple myeloma having undergone autograft

Ongoing
2
43
Europe
ZOMETA, PROLEUKIN, ZOMETA, PROLEUKIN
AZIENDA OSPEDALIERA PISANA
Patients with multiple myeloma having undergone autograft
 
 
2011-001474-25: Subcutaneous administration of Interleukin-2 prior to surgical intervention in case of sonographically and cytologically involved sentinel node

Ongoing
2
20
Europe
Proleukin, Proleukin
Klinik für Dermatologie, Venerologie und Allergologie; Charité - Universitätsmedizin Berlin, AG Voit (Research fund, administered by Prof. Christiane Voit)
The trial is planned in a neo-adjuvant setting for a 4-weeks period in Melanoma patients with stage III. The stage is to be discovered by ultrasound and veriefied by fine needle punctere and cytology.
 
 
2013-001188-22: Immunologic system stimulation as maintaining therapy in hematological cancer Stimolazione del sistema immunologico come terapia di mantenimento nel tumore ematologico

Ongoing
2
43
Europe
ZOMETA, PROLEUKIN, ZOMETA, PROLEUKIN
AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA, Regione Toscana e Ministero della Salute
Multiple Myeloma patients underwent to autologous bone marrow transplant Pazienti adulti affetti da mieloma multiplo sottoposto a trapianto di cellule staminali autologhe
 
 
2016-000581-31: RESTORE IMMUNE COMPETENCE AGAINST CANCER CELLS IN BREAST CARCINOMA RESISTANT TO STANDARD TREATMENTS ATTIVAZIONE DELLA RISPOSTA IMMUNITARIA IN PAZIENTI RESISTENTI AL TRATTAMENTO STANDARD - studio “TRANSLATE - breast”

Ongoing
2
28
Europe
ENDOXAN, PROLEUKIN, Coated tablet, Powder for solution for injection, ENDOXAN BAXTER - 50 MG COMPRESSE RIVESTITE 50 COMPRESSE, PROLEUKIN - INIETTABILE 1 FLAC 18.000.000 UI 1 ML
AZIENDA SANITARIA OSPEDALIERA S.CROCE E CARLE CUNEO, RETE ONCOLOGICA DEL PIEMONTE E VALLE D'AOSTA
METASTATIC BREAST CANCER (MBC) CARCINOMA MAMMARIO METASTATICO, METASTATIC BREAST CANCER (MBC) CARCINOMA MAMMARIO METASTATICO, Diseases [C] - Cancer [C04]
 
 
2016-000578-39: RESTORE IMMUNE COMPETENCE AGAINST CANCER CELLS IN METASTATIC COLON-RECTAL CARCINOMA RESISTANT TO STANDARD TREATMENTS TRANSLATE – Colon-rectal STUDY ATTIVAZIONE DELLA RISPOSTA IMMUNITARIA IN PAZIENTI RESISTENTI AL TRATTAMENTO STANDARD - studio “TRANSLATE – colon-retto”

Ongoing
2
28
Europe
ENDOXAN, proleukin, Coated tablet, Powder for solution for injection, ENDOXAN BAXTER - 50 MG COMPRESSE RIVESTITE 50 COMPRESSE, PROLEUKIN - INIETTABILE 1 FLAC 18.000.000 UI 1 ML
AZIENDA SANITARIA OSPEDALIERA S.CROCE E CARLE CUNEO, Rete Oncologica del Piemonte e valle d'Aosta
COLORECTAL METASTATIC CANCER CARCINOMA COLON-RETTO METASTATICO, COLORECTAL METASTATIC CANCER CARCINOMA COLON-RETTO METASTATICO, Diseases [C] - Cancer [C04]
 
 
2016-000580-17: RESTORE IMMUNE COMPETENCE AGAINST CANCER CELLS IN RENAL CELL CARCINOMA RESISTANT TO STANDARD TREATMENTS TRANSLATE – kidney STUDY ATTIVAZIONE DELLA RISPOSTA IMMUNITARIA IN PAZIENTI RESISTENTI AL TRATTAMENTO STANDARD NEL CARCINOMA RENALE METASTATICO (mRCC) - studio “TRANSLATE - rene”

Ongoing
2
28
Europe
ENDOXAN, proleukin, Coated tablet, Powder for solution for injection, ENDOXAN BAXTER - 50 MG COMPRESSE RIVESTITE 50 COMPRESSE, PROLEUKIN - INIETTABILE 1 FLAC 18.000.000 UI 1 ML
AZIENDA SANITARIA OSPEDALIERA S.CROCE E CARLE CUNEO, Rete Oncologica del Piemonte e valle d'Aosta
metastatic renal cell carcinoma (mRCC) CARCINOMA RENALE METASTATICO, metastatic renal cell carcinoma (mRCC) CARCINOMA RENALE METASTATICO, Diseases [C] - Cancer [C04]
 
 
2016-000579-26: RESTORE IMMUNE COMPETENCE AGAINST CANCER CELLS IN PROSTATE CARCINOMA RESISTANT TO STANDARD TREATMENTS TRANSLATE – prostate STUDY ATTIVAZIONE DELLA RISPOSTA IMMUNITARIA IN PAZIENTI RESISTENTI AL TRATTAMENTO STANDARD - studio “TRANSLATE - prostata”

Ongoing
2
28
Europe
Endoxan, PROLEUKIN, Coated tablet, Powder for solution for injection, ENDOXAN BAXTER - 50 MG COMPRESSE RIVESTITE 50 COMPRESSE, PROLEUKIN - INIETTABILE 1 FLAC 18.000.000 UI 1 ML
AZIENDA SANITARIA OSPEDALIERA S.CROCE E CARLE CUNEO, RETE ONCOLOGICA DEL PIEMONTE E VALLE D'AOSTA
metastatic castration resistant prostate carcinoma (mCRPC) carcinoma della prostata metastatico resistente alla castrazione (mCRPC), metastatic castration resistant prostate carcinoma (mCRPC) carcinoma della prostata metastatico resistente alla castrazione (mCRPC), Diseases [C] - Cancer [C04]
 
 
NCT02340676: A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD

Active, not recruiting
2
25
US
Extracorporeal Photopheresis (ECP), Interleukin-2, IL-2, Proleukin®
Dana-Farber Cancer Institute, Prometheus Laboratories
Chronic Graft-versus-host-disease
08/17
12/25
2017-002126-20: Aldesleukin Therapy in Type 1 Diabetes

Ongoing
2
45
Europe
Aldesleukin, Aldesleukin, Solution for injection in pre-filled pen, Proleukin
University of Oxford, JDRF
Type 1 Diabetes, Type 1 Diabetes, Diseases [C] - Immune System Diseases [C20]
 
 
NCT02748564: Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

Terminated
2
10
US
Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2, Laboratory Biomarker Analysis, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
Rutgers, The State University of New Jersey, National Cancer Institute (NCI)
Metastatic Melanoma, Stage III Mucosal Melanoma of the Head and Neck, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Skin Melanoma, Stage IVA Mucosal Melanoma of the Head and Neck, Stage IVB Mucosal Melanoma of the Head and Neck, Stage IVC Mucosal Melanoma of the Head and Neck
10/18
06/23
2018-003635-30: NA Traitement par IL2 à faible dose chez des femmes ayant des fausses couches spontanées précoces répétées inexpliquées

Not yet recruiting
2
10
Europe
Proleukin, L03A-CO1, Powder for concentrate for solution for injection/infusion, Proleukin
ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP), ANR
NA Femmes ayant des fausses couches spontanées précoces répétées inexpliquées (FCRI), NA Femmes ayant des fausses couches spontanées précoces répétées inexpliquées (FCRI), Diseases [C] - Immune System Diseases [C20]
 
 
NCT02964078: Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer

Active, not recruiting
2
27
US
Pembrolizumab, anti-PD-1 antibody, Keytruda™, Interleukin-2, aldesleukin, Proleukin™, IL-2
H. Lee Moffitt Cancer Center and Research Institute, Merck Sharp & Dohme LLC, Prometheus Laboratories
Kidney Cancer
03/19
10/25
NCT04135092: Single Patient Protocol: A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab

No Longer Available
2
NA
Individual Patient TCR Transduced PBL, Cyclophosphamide, Fludarabine, Aldesleukin, Pembrolizumab
National Institutes of Health Clinical Center (CC)
 
 
NCT03850691: Radiation and Combination Immunotherapy for Melanoma

Completed
2
4
US
Aldesleukin: All Patients, IL-2, Nivolumab: Cohort 1 (Cutaneous), Nivolumab: Cohort 2 (Ocular), Ipilimumab: Cohort 2 (Ocular)
Masonic Cancer Center, University of Minnesota
Metastatic Melanoma
05/21
12/22
2020-003629-45: A clinical study to investigate if the investigational product, called LN -145 (also known as Tumor Infiltrating Lymphocytes) is safe and beneficial in the treatment of patients with Metastatic Non-Small-Cell Lung Cancer

Not yet recruiting
2
148
Europe
LN-145, Fludarabine Phosphate, Cyclophosphamide Injection, Proleukin, LN-145, Solution for infusion, Concentrate for solution for infusion, Powder for solution for infusion, Powder for solution for injection, Powder for solution for injection/infusion, Fludarabine Phosphate, Cyclophosphamide, Proleukin
Iovance Biotherapeutics, Inc., Iovance Biotherapeutics, Inc.
Metastatic Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Diseases [C] - Cancer [C04]
 
 
NCT01659151: Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma

Active, not recruiting
2
17
US
High Dose Interleukin-2 (IL-2), aldesleukin, Proleukin, ACT with TIL Infusion, Vemurafenib, Zelboraf, B-Raf enzyme inhibitor, Lymphodepletion, fludarabine, Fludara, cyclophosphamide, Neostar, Cytoxan
H. Lee Moffitt Cancer Center and Research Institute
Metastatic Melanoma
10/21
09/25
NCT01857934: Therapy for Children With Advanced Stage Neuroblastoma

Active, not recruiting
2
153
US
cyclophosphamide, Cytoxan(R), topotecan, Hycamtin(R), hu14.18K322A, humanized anti-GD2 antibody, monoclonal antibody, dinutuximab, peripheral blood stem cell harvest, PBSCH, surgical resection, cisplatin, Platinol-AQ(R), etoposide, VP16, Vepesid(R), Etopophos(R), doxorubicin, Adriamycin(R), vincristine, Oncovin(R), busulfan, Busulfex(R), melphalan, L-phenylalanine mustard, Phenylalanine mustard, L-PAM, L-sarcolysin, Alkeran(R), peripheral blood stem cell transplantation, PBSCT, natural killer cell infusion, NK cell infusion, radiation therapy, GM-CSF, sargramostim, Leukine(R), granulocyte macrophage colony stimulating factor, G-CSF, Granulocyte colony stimulating factor, Neupogen(R), Filgrastim, mesna, Mesnex(R), levetiracetam, Keppra, interleukin-2, IL-2, aldesleukin, Proleukin(R), Isotretinoin, 13-cis retinoic acid, CliniMACS, Cell Selection System
St. Jude Children's Research Hospital, Cookies for Kids' Cancer, CURE Childhood Cancer, Inc.
Neuroblastoma
10/21
12/25
ITAD, NCT03782636: Interleukin-2 Therapy of Autoimmunity in Diabetes

Active, not recruiting
2
41
Europe
Aldesleukin, Placebo
University of Oxford, Oxford Clinical Trials Research Unit (OCTRU), Centre for Statistics in Medicine, Oxford, JDRF, Wellcome
Type1 Diabetes
04/22
09/22
NCT04383067: A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients

Recruiting
2
20
RoW
Tumor Infiltrating Lymphocytes (TIL), Proleukin
Sheba Medical Center
Metastatic Urothelial Carcinoma
06/22
06/23
NCT00534469: Auto BMT for Non-M3 AML in 1st Remission in Pts

Active, not recruiting
2
60
NA
aldesleukin, Proleukin, filgrastim, Neupogen, busulfan, Myleran, Busulfex IV, cytarabine, cytosine arabinoside, ara-C, arabinofuranosyl cytidine, Cytosar-U, etoposide, VP-16, Vepesid, Toposar, Etophosphos, idarubicin, Idamycin, Zavedos, 4-demethoxydaunorubicin, autologous hematopoietic stem cell transplantation, bone marrow transplantation, peripheral blood stem cell transplantation, total-body irradiation
City of Hope Medical Center, National Cancer Institute (NCI)
Leukemia
12/22
08/25
NCT03501381: High Dose IL 2 and Entinostat in RCC

Active, not recruiting
2
46
US
Entinostat, Interleukin-2, aldesleukin
Roberto Pili, Indiana University Melvin and Bren Simon Cancer Center, Syndax Pharmaceuticals, Clinigen, Inc.
Renal Cell Carcinoma
01/23
04/24
NCT01697527: Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies

Active, not recruiting
2
6
US
aldesleukin, IL-2, Proleukin, recombinant human interleukin-2, recombinant interleukin-2, fludarabine phosphate, 2-F-ara-AMP, Beneflur, Fludara, cyclophosphamide, CPM, CTX, Cytoxan, Endoxan, Endoxana, laboratory biomarker analysis, NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL, anti-NY-ESO-1 TCR gene-engineered lymphocytes, anti-NY-ESO-1 TCR retroviral vector-transduced lymphocytes, dendritic cell vaccine therapy, fludeoxyglucose F 18, 18FDG, FDG, positron emission tomography, FDG-PET, PET, PET scan, tomography, emission computed
Jonsson Comprehensive Cancer Center
Malignant Neoplasm
11/25
11/26
NCT02306954: Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer

Active, not recruiting
2
84
US
High Dose IL-2, Proleukin, SBRT
Providence Health & Services, Prometheus Laboratories, Cytokine Working Group
Renal Cell Carcinoma
09/20
12/26
NCT01174121: Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

Recruiting
2
332
US
Pembrolizumab (Keytruda), Fludarabine, Cyclophosphamide, Aldesleukin, Young TIL
National Cancer Institute (NCI)
Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Metastatic Ovarian Cancer, Metastatic Breast Carcinoma, Metastatic Endocrine Tumors/ Neuroendocrine Tumors
12/28
12/29
NCT02027935: CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma

Completed
2
16
US
Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2, Autologous CD8+ Melanoma Specific T Cells, Autologous Melanoma Specific Cytotoxic T Lymphocytes, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Laboratory Biomarker Analysis
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Metastatic Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7
04/24
04/24
NCT01319565: Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...

Completed
2
102
US
Aldesleukin, Cyclophosphamide, Fludarabine, Young TIL, Total Body Irradiation (TBI)
National Cancer Institute (NCI)
Metastatic Melanoma, Skin Cancer
09/24
09/24
NCI-2018-00918, NCT03449108: LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

Active, not recruiting
2
30
US
Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2, Autologous Tumor Infiltrating Lymphocytes LN-145, Autologous TILs LN-145, Autologous Tumor-infiltrating Lymphocytes LN-145, LN-145, LN145, Autologous Tumor Infiltrating Lymphocytes LN-145-S1, Autologous TILs LN-145-S1, Autologous Tumor-infiltrating Lymphocytes LN-145-S1, LN 145-S1, LN-145-S1, LN145-S1, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine, Fluradosa, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
M.D. Anderson Cancer Center, Iovance Biotherapeutics, Inc., National Cancer Institute (NCI)
Bone Sarcoma, Dedifferentiated Chondrosarcoma, Giant Cell Tumor of Bone, Malignancy in Giant Cell Tumor of Bone, Malignant Solid Neoplasm, Ovarian Carcinosarcoma, Platinum-Resistant Ovarian Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Osteosarcoma, Recurrent Ovarian Carcinoma, Refractory Osteosarcoma, Soft Tissue Sarcoma, Thyroid Gland Anaplastic Carcinoma, Thyroid Gland Squamous Cell Carcinoma, Undifferentiated High Grade Pleomorphic Sarcoma of Bone, Triple Negative Breast Cancer
04/27
04/27
NCT04562129: IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

Recruiting
2
29
US
Interleukin-2, Aldesleukin, Ipilimumab, Nivolumab
H. Lee Moffitt Cancer Center and Research Institute, Clinigen, Inc.
Melanoma Stage III, Melanoma Stage IV, Inoperable Disease
08/25
11/29
NCT02133196: T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

Recruiting
2
85
US
Aldesleukin, Fludarabine, Cyclophosphamide, Young TIL
National Cancer Institute (NCI)
Advanced Non-Small Cell Lung Cancer, Squamous Cell Carcinoma, Advanced NSCLC, Adenosquamous Carcinoma, Adenocarcinoma
10/25
10/25
NCT05754684: Quadruple Immunotherapy for Neuroblastoma

Recruiting
2
29
RoW
Natural killer cell, NK cell, Dinutuximab beta, Ch14.18, Interleukin-2, Aldesleukin, Granulocyte-Macrophage Colony-Stimulating Factor, Sargramostim, Spironolactone, Aldactone, Naxitamab, hu3F8
Hong Kong Children's Hospital, The University of Hong Kong
Neuroblastoma Recurrent
12/24
12/25
NCT05686226: E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

Recruiting
2
20
US
E7 TCR-T cells, E7 TCR, HPV TCR, TIL, Adoptive cell transfer, CAR-T, TCR, Aldesleukin, Proleukin
Christian Hinrichs, National Cancer Institute (NCI), Iovance Biotherapeutics, Inc.
Cervical Cancer, Throat Cancer, Oropharynx Cancer, Anal Cancer, Vulva Cancer, Vaginal Cancer, Penile Cancer, Metastatic Cancer, HPV-Related Malignancy, HPV-Related Carcinoma, HPV-Related Cervical Carcinoma, HPV-Related Squamous Cell Carcinoma, HPV-Related Adenocarcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Associated Vaginal Adenocarcinoma, HPV-Related Adenosquamous Carcinoma, HPV-Related Endocervical Adenocarcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, HPV Positive Rectal Squamous Cell Carcinoma
01/27
01/27
NCT02621021: A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab

Recruiting
2
170
US
young TIL, Pembrolizumab, Aldesleukin, Fludarabine, Cyclophosphamide
National Cancer Institute (NCI)
Melanoma
06/28
06/29
NCT06690281: A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies

Recruiting
2
65
US
KRAS TCR-Transduced PBL, Aldesleukin, Fludarabine, Cyclophosphamide
National Cancer Institute (NCI)
Gastrointestinal Carcinoma, Pancreatic Cancer, Hepatocellular Cancer, Cholangiocarcinoma, Duodenal Cancer, Colorectal Cancer, Small Bowel Cancer, Metastatic Cancers
06/29
06/33
DTIC, NCT00553618: Adjuvant, Combined Interleukin 2 (Proleukin) and (Dacarbazine) in High-risk Melanoma Patients

Active, not recruiting
2
160
US
Proleukin and Dacarbazine, Proleukin, Dacarbazine
University of Louisville, James Graham Brown Cancer Center
Metastatic Melanoma
08/25
08/26
NCT05155033: Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

Recruiting
2
78
US
Pembrolizumab, Aldesleukin
National Cancer Institute (NCI)
Metastatic Melanoma, Advanced Locoregional Melanoma, Metastatic Renal Cell Carcinoma, Clear Cell Histology
09/26
09/27
NCT03412877: Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

Recruiting
2
270
US
Cyclophosphamide, Fludarabine, Aldesleukin, Individual Patient TCR-Transduced PBL, Pembrolizumab (KEYTRUDA(R))
National Cancer Institute (NCI)
Endocrine Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer, Gastrointestinal/Genitourinary Cancers, Neuroendocrine Tumors, Multiple Myeloma
03/27
03/28
NCT04102436: Non-Viral TCR Gene Therapy

Withdrawn
2
210
US
Fludarabine, Cyclophosphamide, Aldesleukin, Sleeping Beauty Transposed PBL
National Cancer Institute (NCI)
Endocrine/Neuroendocrine, Non-Small Cell Lung Cancer, Breast Cancer, Gastrointestinal/Genitourinary Cancers, Ovarian Cancer
03/24
03/24
NCT00338377: Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma

Active, not recruiting
2
1230
US
Dendritic Cell Immunization, Cyclophosphamide, Cytoxan, Neosar, Fludarabine, Fludarabine Phosphate, Fludara, T-Cells, Interleukin-2, IL-2, Proleukin, Mesna, Sodium 2-mercaptoethanesulfonate, Mesnum, Mesnex, NSC-113891, Intrathecal T-Cells, Intrathecal Interleukin-2
M.D. Anderson Cancer Center, Prometheus Laboratories, Key Biologics, LLC, National Cancer Institute (NCI), Adelson Medical Research
Melanoma
02/30
02/30
2016-003578-42: Infusion of activated NK cells for the treatment of children, adolescents and young adults with sarcomas. Infusión de células NK activadas para el tratamiento de niños, adolescentes y adultos jóvenes con sarcomas.

Ongoing
1/2
10
Europe
NK cells, Proleukin, Injection, Powder for solution for injection/infusion, PROLEUKIN
Antonio Pérez-Martínez, Servicio de Hemato-Oncología Infantil. Hospital Universitario La Paz.
Sarcoma Sarcoma, Sarcoma Sarcoma, Diseases [C] - Cancer [C04]
 
 
NCT01038778: Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer

Active, not recruiting
1/2
47
US
Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Entinostat, HDAC inhibitor SNDX-275, MS 27-275, MS 275, MS-275, MS275, SNDX 275, SNDX-275, SNDX275, Fludeoxyglucose F-18, 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Laboratory Biomarker Analysis, Pharmacological Study, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT
National Cancer Institute (NCI)
Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
05/19
02/26
2021-005110-34: ICT01 in combination with IL-2 in patients with advanced solid tumors

Not yet recruiting
1/2
42
Europe
ICT01, proleukin, Solution for infusion, Powder for solution for injection, PROLEUKIN®
ImCheck Therapeutics, Inc., ImCheck Therapeutics, Inc.
Relapsed/refractory patients with advanced solid tumors : metastatic colorectal cancer (CRC) or metastatic ovarian cancer or metastatic castration-resistant prostate cancer (mCRPC) or metastatic pancreatic ductal adenocarcinoma (PDAC), Relapsed/refractory patients with metastatic cancer : colorectal or ovarian or prostate or pancreatic ductal adenocarcinoma, Diseases [C] - Cancer [C04]
 
 
NCT05207722: CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

Terminated
1/2
1
US
CYNK-101, Pembrolizumab, Keytruda®, Trastuzumab, Herceptin®, Recombinant Human Interleukin-2, proleukin, Cyclophosphamide, cytoxan, Fludarabine, fludara, Mesna
Celularity Incorporated
Metastatic HER2 Positive Gastroesophageal Junction Cancer
02/24
02/24
NCI-2014-02655, NCT01740557: Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma

Completed
1/2
10
US
Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2, CXCR2-transduced Autologous Tumor Infiltrating Lymphocytes, CXCR2-transduced Autologous TILs, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, Laboratory Biomarker Analysis, NGFR-transduced Autologous T Lymphocytes, Quality-of-Life Assessment, Quality of Life Assessment
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
04/23
04/23
2019LS002, NCT04426669: A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering

Active, not recruiting
1/2
20
US
Cyclophosphamide, Fludarabine, Tumor-Infiltrating Lymphocytes (TIL), Aldesleukin, Interleukin-2, IL-2
Intima Bioscience, Inc., Masonic Cancer Center, University of Minnesota
Gastrointestinal Epithelial Cancer, Gastrointestinal Neoplasms, Cancer of Gastrointestinal Tract, Cancer, Gastrointestinal, Gastrointestinal Cancer, Colo-rectal Cancer, Pancreatic Cancer, Gall Bladder Cancer, Colon Cancer, Esophageal Cancer, Stomach Cancer
01/26
01/26
NK4AML, NCT04347616 / 2019-001929-27: Natural Killer-cell Therapy for Acute Myeloid Leukemia

Recruiting
1/2
23
Europe
UCB-NK cells, IL-2, Aldesleukin
Radboud University Medical Center, Dutch Cancer Society
Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, Relapsed, Adult
09/25
09/25
NCT03318900: T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer

Completed
1/2
5
US
Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2, CD8-Positive T-Lymphocyte, CD8 Cell, CD8 Lymphocyte, CD8 Lymphocytes, CD8+ T Cell, CD8+ T Lymphocyte, CD8+ T Lymphocytes, CD8+ T-Lymphocyte, CD8-Positive Lymphocyte, CD8-Positive Lymphocytes, CD8-Positive T-Lymphocytes, T8 Cell, T8 Cells, T8 Lymphocyte, T8 Lymphocytes, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Leukapheresis, Leukocytopheresis, Therapeutic Leukopheresis, Utomilumab, PF 05082566, PF 5082566, PF-05082566, PF-2566
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
COL6A3 Positive, HLA-A*0201 Positive Cells Present, PRAME Positive, Recurrent Ovarian Carcinoma
12/23
12/23
NCT03658785: Immunotherapy for the Treatment of Advanced Solid Tumor

Recruiting
1/2
40
RoW
TIL, Aldesleukin, IL-2, Cyclophosphamide, CTX, Fludarabine
Tongji Hospital
Recurrence Tumor, Metastatic Cancer, Solid Tumor
12/24
12/25
EVICTION-2, NCT05307874 / 2021-005110-34: Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid Tumors

Active, not recruiting
1/2
56
Europe
ICT01, Proleukin Injectable Product, IL-2, Pembrolizumab injection
ImCheck Therapeutics, ILife Consulting, Exystat
Solid Tumor, Adult
09/25
12/25
NCT05821686: Efficacy of Interleukin-2 in Triple Negative Breast Cancer

Not yet recruiting
1/2
10
NA
Human Interleukin-2 (IL-2) (Proleukin)
Nova Scotia Health Authority
Triple Negative Breast Cancer
04/28
04/28
NCT05267626: Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Recruiting
1/2
159
US, RoW
AU-007, Aldesleukin, Avelumab, Nivolumab
Aulos Bioscience, Inc.
Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer
08/25
09/25
NCT04089891: A Study in Patients With Metastatic Gastrointestinal Epithelial Cancer Administering Tumor-Infiltrating Lymphocytes in Which the Gene Encoding CISH Was Inactivated Using the CRISPR/Cas9 System

Not yet recruiting
1/2
41
NA
Lymphodepleting Chemotherapy Regimen, Tumor-Infiltrating Lymphocytes (TIL), Aldesleukin
Masonic Cancer Center, University of Minnesota
Gastrointestinal Epithelial Cancer
10/24
10/24
CheckCell-2, NCT05566223: CISH Inactivated TILs in the Treatment of NSCLC

Not yet recruiting
1/2
70
US
Fludarabine, Fludara, Cyclophosphamide, Cytoxan, CISH Inactivated TIL, Aldesleukin, Proleukin, Interleukin-2, IL-2, Pembrolizumab, Keytruda
Intima Bioscience, Inc.
Carcinoma, Non-Small-Cell Lung, Metastatic Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Adenocarcinoma of Lung, Large Cell Lung Cancer
11/25
11/27
NCT05194735: Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors

Active, not recruiting
1/2
180
US
Neoantigen specific TCR-T cell drug product, Aldesleukin (IL-2)
Alaunos Therapeutics
Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer, Non-small Cell Lung Cancer, Cholangiocarcinoma, Ovarian Cancer, Endometrial Cancer, Ovarian Carcinoma, Ovary Neoplasm, Squamous Cell Lung Cancer, Adenocarcinoma of Lung, Adenosquamous Cell Lung Cancer
11/24
11/24
Indapta-Trial-1, NCT06119685: IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Recruiting
1/2
128
US
IDP-023, Rituximab, Rituxan, Daratumumab, Darzalex, Interleukin-2, Proleukin, Cyclophosphamide, Fludarabine, Mesna, Isatuximab, Sarclisa
Indapta Therapeutics, INC.
NHL, Multiple Myeloma, Blood Cancer, Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma
12/25
12/29
NCT02858310: E7 TCR T Cells for Human Papillomavirus-Associated Cancers

Recruiting
1/2
180
US
E7 TCR cells, Aldesleukin, Fludarabine, Cyclophosphamide
National Cancer Institute (NCI)
Papillomavirus Infections, Cervical Intraepithelial Neoplasia, Carcinoma In Situ, Vulvar Neoplasms, Vulvar Diseases
12/25
01/26
NCT05639972: E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

Recruiting
1/2
15
US
E7 TCR-T cells, E7 TCR, HPV TCR, TIL, Adoptive cell transfer, CAR-T, TCR, Aldesleukin, Proleukin
Christian Hinrichs, Iovance Biotherapeutics, Inc.
HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma, HPV-Related Malignancy, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Adenocarcinoma, HPV-Related Adenosquamous Carcinoma, HPV-Related Squamous Cell Carcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, HPV-Related Endocervical Adenocarcinoma, Cervical Cancer, Oropharynx Cancer, Anal Cancer, Vulvar Cancer, Penile Cancer, Vaginal Cancer
10/26
10/26
NCT02830724: Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

Recruiting
1/2
124
US
Cyclophosphamide, Fludarabine, Aldesleukin, Anti-hCD70 CAR transduced PBL
National Cancer Institute (NCI)
Pancreatic Cancer, Renal Cell Cancer, Breast Cancer, Melanoma, Ovarian Cancer
01/27
01/28
NCT03190941 / 2017-000268-14: Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

Recruiting
1/2
110
US
Cyclophosphamide, Fludarabine, Anti-KRAS G12V mTCR PBL, Aldesleukin
National Cancer Institute (NCI)
Pancreatic Cancer, Gastric Cancer, Gastrointestinal Cancer, Colon Cancer, Rectal Cancer
06/27
06/28
19-C-0017, NCT03745326: Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

Recruiting
1/2
70
US
Cyclophosphamide, Fludarabine, Aldesleukin, anti-KRAS G12D mTCR PBL
National Cancer Institute (NCI)
Gastrointestinal Cancer, Pancreatic Cancer, Gastric Cancer, Colon Cancer, Rectal Cancer
12/27
12/28
NCT05296564: Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers

Recruiting
1/2
3
RoW
CYCLOPHOSPHAMIDE and FLUDARABIN, CYTOXAN, Cyclophosphamide, HBI 0201-ESO TCRT, Aldesleukin, Interleukin-2
Hadassah Medical Organization
Sarcoma, Synovial, Sarcoma,Soft Tissue, Melanoma Stage IV, Triple Negative Breast Cancer, Metastatic Cancer, Non Small Cell Lung Cancer, Bladder Urothelial Carcinoma, Neuroblastoma, Metastatic, Ovary Cancer
12/27
12/27
NCT01909206: A Phase I Trial of Anti-PD-1, Anti-CD137 and TIL

Not yet recruiting
1
24
US
Nivolumab, Anti-PD-1 blocking antibody, BMS-936558, Tumor Infiltrating Lymphocyte (TIL), Cyclophosphamide, Cytoxan, Mesna, Sodium 2-mercaptoethanesulfonate, Mesnum, Mesnex, NSC-113891, Fludarabine, Fludara, TIL Infusion, High Dose Interleukin-2 (IL-2), Aldesleukin, Proleukin
H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb, Prometheus Laboratories, National Cancer Institute (NCI)
Metastatic Melanoma
12/16
12/16
NCT03017131: Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Active, not recruiting
1
9
US
Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Decitabine, 5-Aza-2'-deoxycytidine, Dacogen, Decitabine for Injection, Deoxyazacytidine, Dezocitidine, Genetically Engineered NY-ESO-1-specific T Lymphocytes, Laboratory Biomarker Analysis
Roswell Park Cancer Institute, National Cancer Institute (NCI)
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
03/20
03/32
NCI-2018-01758, NCT03691376: Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Terminated
1
4
US
Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, recombinant human interleukin-2, Autologous NY-ESO-1-specific CD8-positive T Lymphocytes, Cellular Therapy, Cell Therapy, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalanum, Phenylalanine Mustard, Phenylalanine nitrogen mustard, Sarcoclorin, Sarkolysin, WR-19813
Roswell Park Cancer Institute
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Platinum-Sensitive Fallopian Tube Carcinoma, Platinum-Sensitive Ovarian Carcinoma, Platinum-Sensitive Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Refractory Fallopian Tube Carcinoma, Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Carcinoma
01/21
06/24
CA209-9JA, NCT03215810: Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer

Completed
1
20
US
Tumor-infiltrating Lymphocytes (TIL), TIL, Nivolumab, Opdivo, Cyclophosphamide, Cytoxan, Fludarabine, Fludara, Tumor-infiltrating Lymphocyte Therapy, Interleukin-2 (IL2), IL2, Proleukin®
H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb, Prometheus Inc., Stand Up To Cancer, Iovance Biotherapeutics, Inc.
Non-Small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, Squamous Cell Carcinoma, Advanced NSCLC, Adenosquamous Carcinoma, Adenocarcinomas
02/21
06/23
NCT06307301: Study in ALS With Abatacept & IL-2

Active, not recruiting
1
5
US
Abatacept Injection [Orencia] and Proleukin (aldesleukin)
The Methodist Hospital Research Institute
Amyotrophic Lateral Sclerosis
10/24
10/24
NCT05821153: Low Dose IL2 Immunotherapy in AD

Completed
1
8
US
Aldesleukin
The Methodist Hospital Research Institute
Alzheimer Disease
04/22
04/22
NCT04545827: Study to Evaluate the Safety of IMM-01 in Patients With Advanced Solid Tumours

Not yet recruiting
1
10
NA
IMM-01, Losartan, Proleukin
Modulate Therapeutics Ltd
Solid Tumor, Solid Carcinoma, Neoplasms, Uveal Melanoma, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Car. - Esophagus, Renal Cell Carcinoma, Colorectal Cancer, Advanced Cancer
07/22
07/22
NCT03260504: Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer

Terminated
1
6
US
Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Immunoglobulin G4, Anti-(Human Programmed Cell Death 1)
University of Washington, Merck Sharp & Dohme LLC, Prometheus Laboratories
Advanced Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Metastatic Clear Cell Renal Cell Carcinoma
07/22
07/22
NCI-2018-00926, NCT03450122: Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma

Checkmark Initiation of pivotal monotherapy trial
Mar 2018 - Mar 2018: Initiation of pivotal monotherapy trial
Completed
1
15
US
Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2, Autologous NY-ESO-1-specific CD8-positive T Lymphocytes, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Dendritic Cell-targeting Lentiviral Vector ID-LV305, DCvex-NY-ESO-1, ID-LV305
M.D. Anderson Cancer Center
HLA-A*0201 Positive Cells Present, NY-ESO-1 Positive Tumor Cells Present, Recurrent Myxoid Liposarcoma, Recurrent Synovial Sarcoma
12/22
12/22
NCT03068624: Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

Active, not recruiting
1
34
US
Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2, Autologous CD8+ SLC45A2-specific T Lymphocytes, Autologous SLC45A2-specific CTLs, Autologous SLC45A2-specific Cytotoxic T Lymphocytes, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma
12/22
07/25
NCT04551885: FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Terminated
1
12
US
FT516, Avelumab, Bavencio, Cyclophosphamide, Fludarabine, IL-2, Proleukin, Aldesleukin
Fate Therapeutics
Solid Tumor, Adult
08/23
08/23
NCT05483491: KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer

Recruiting
1
30
US
KK-LC-1 TCR-T cells, KK-LC-1 TCR, TIL, Adoptive cell transfer, CAR-T, TCR, Aldesleukin, Proleukin
Christian Hinrichs, National Cancer Institute (NCI), Iovance Biotherapeutics, Inc.
Gastric Cancer, Breast Cancer, Cervical Cancer, Lung Cancer
09/26
12/28
NYESO SCT, NCT03240861: Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer

Terminated
1
5
US
18F-FHBG, Reporter Probe 18F-FHBG, Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2, Busulfan, 1, 4-Bis[methanesulfonoxy]butane, BUS, Bussulfam, Busulfanum, Busulfex, Busulphan, CB 2041, CB-2041, Glyzophrol, GT 41, GT-41, Joacamine, Methanesulfonic Acid Tetramethylene Ester, Methanesulfonic acid, tetramethylene ester, Mielucin, Misulban, Misulfan, Mitosan, Myeleukon, Myeloleukon, Myelosan, Mylecytan, Myleran, Sulfabutin, Tetramethylene Bis(methanesulfonate), Tetramethylene bis[methanesulfonate], WR-19508, Cellular Therapy, Cell Therapy, Computed Tomography, CAT, CAT Scan, Computerized Axial Tomography, Computerized Tomography, CT, CT SCAN, tomography, Filgrastim, Filgrastim XM02, Filgrastim-sndz, G-CSF, Granix, Neupogen, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, rG-CSF, Tbo-filgrastim, Tevagrastim, Zarxio, Fludarabine, Fluradosa, Leukapheresis, Leukocytopheresis, Therapeutic Leukopheresis, Plerixafor, AMD 3100, JM-3100, Mozobil, SDZ SID 791, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET SCAN, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging
Jonsson Comprehensive Cancer Center, California Institute for Regenerative Medicine (CIRM)
HLA-A*0201 Positive Cells Present, Locally Advanced Malignant Neoplasm, NY-ESO-1 Positive, Unresectable Malignant Neoplasm, Sarcoma
10/23
10/23
NCT06138587: Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation

Recruiting
1
15
US
Cytokine Induced Memory-like Natural Killer Cells, CIML NK cells, Interleukin-2, Aldesleukin, Proleukin
Dana-Farber Cancer Institute
Acute Myeloid Leukemia, Leukemia, Leukemia, Myeloid, Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Myeloproliferative Disorders
02/26
11/26
NCT06152809: CIML NK Cells With Venetoclax for AML

Recruiting
1
10
US
Cytokine-Induced Memory-like Natural Killer Cells, CIML NK Cells, Interleukin-2, Aldesleukin, Proleukin, IL-2, Venetoclax, C45H50ClN7O7S
Dana-Farber Cancer Institute, The Leukemia and Lymphoma Society
Acute Myeloid Leukemia, Acute Myeloid Leukemia Recurrent, Leukemia, Leukemia, Myeloid
11/26
11/27
NCT06236425: TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC

Active, not recruiting
1
7
US
TBio-4101, Tumor-Infiltrating Lymphocyte, Pembrolizumab, Keytruda, Platinum based chemotherapy, Cisplatin, Carboplatin/5-FU, Cyclophosphamide, Cytoxan, Fludarabine, Fludara, Aldesleukin, Interleukin-2, IL-2
H. Lee Moffitt Cancer Center and Research Institute, Turnstone Biologics, Corp.
Squamous Cell Carcinoma of Head and Neck, Metastatic Squamous Cell Carcinoma
08/26
08/26
NCT01590069: Aerosolized Aldesleukin in Treating Patients With Lung Metastases

Active, not recruiting
1
70
US
Aerosolized Aldesleukin, Aerosolized Recombinant IL-2, Laboratory Biomarker Analysis
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Metastatic Malignant Neoplasm in the Lung, Metastatic Melanoma, Metastatic Osteosarcoma, Metastatic Renal Cell Cancer, Sarcoma, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Osteosarcoma AJCC v7, Stage IV Renal Cell Cancer AJCC v7
04/26
04/26
 

Download Options